asthma
complex
genet
disord
character
airway
inflamm
revers
airflow
obstruct
result
symptom
complex
wheez
dyspnea
cough
combin
character
multipl
phenotyp
may
differ
basi
age
onset
trigger
factor
respons
treatment
variabl
pattern
revers
acut
exacerb
longstand
diseas
asthma
common
diseas
increas
preval
worldwid
highest
preval
industri
countri
estim
nearli
million
peopl
world
asthma
unit
state
million
peopl
report
symptom
consist
diagnosi
asthma
includ
million
younger
year
nearli
peopl
die
year
asthma
report
underli
caus
death
peopl
asthma
account
nearli
hospit
annual
preval
morbid
asthma
increas
worldwid
concern
asthma
patient
alway
readili
identifi
may
receiv
optim
treatment
diseas
commonli
observ
clinic
atop
diseas
allerg
rhiniti
atop
dermat
asthma
occur
famili
subsequ
famili
aggreg
twin
gene
linkag
studi
provid
evid
support
studi
twin
allow
comparison
monozygot
twin
share
gene
dizygot
twin
share
approxim
gene
greater
occurr
asthma
monozygot
twin
even
rais
differ
environ
evid
genet
compon
famili
studi
asthma
common
children
allerg
asthmat
parent
nonallerg
asthmat
parent
underscor
import
atopi
asthma
occur
less
frequent
children
parent
nonasthmat
nonallerg
appli
specif
risk
ratio
given
famili
difficult
differ
environment
variabl
contribut
develop
asthma
also
differ
popul
preval
asthma
gener
unit
state
one
parent
allerg
asthma
child
approxim
chanc
develop
asthma
parent
allerg
asthma
child
approxim
chanc
inherit
pattern
asthma
complex
genet
disord
similar
hypertens
diabet
mellitu
asthma
classifi
simpli
autosom
domin
recess
sexlink
mode
inherit
polygen
sever
gene
linkag
shown
asthma
summar
tabl
primari
chromosom
region
identifi
includ
chromosom
band
total
ige
eosinophil
interleukin
il
chromosom
major
histocompat
complex
tumor
necrosi
factor
tnf
chromosom
band
highaffin
ige
receptor
chromosom
interferon
ifn
nitric
oxid
synthetas
leukotrien
hydrolas
signal
transduc
activ
transcript
stat
chromosom
cysteinyl
leukotrien
receptor
recent
gene
chromosom
encod
proteinprocess
enzym
metalloproteas
express
lung
fibroblast
myofibroblast
smooth
muscl
cell
found
commonli
associ
asthma
addit
effect
gene
interact
gene
environ
may
also
role
specif
sequenc
identifi
genet
suscept
interact
need
studi
help
understand
import
relationship
gene
environ
overal
asthma
process
pharmacogenet
anoth
key
area
relationship
pharmacogenet
use
variat
drug
respons
differ
individu
result
genet
differ
genet
variat
drug
target
gene
use
predict
clinic
respons
treatment
asthma
alter
cysteinyl
leukotrien
synthesi
glucocorticoid
receptor
muscarin
receptor
phosphodiesteras
may
affect
respons
treatment
differ
class
drug
gene
receiv
extens
attent
candid
gene
asthma
risk
sever
respons
treatment
two
import
code
variant
posit
posit
appear
function
import
linkag
disequilibrium
howev
individu
polymorph
one
genet
locu
may
may
chang
anoth
posit
therefor
bad
polymorph
one
site
may
counter
good
polymorph
anoth
site
point
howev
appear
chromosom
homozyg
asthma
patient
increas
asthmat
exacerb
decreas
peak
expiratori
flow
take
albuterol
regularli
result
confirm
could
signific
effect
onesixth
asthma
patient
unit
state
phenotyp
treat
anoth
exampl
lipoxygenas
pathway
result
synthesi
cysteinyl
leukotrien
promot
region
variant
label
wild
type
nonwild
type
wild
type
variant
common
effect
enzym
thu
produc
leukotrien
less
effect
enzymat
activ
nonwild
type
produc
fewer
leukotrien
consequ
blockag
leukotrien
pathway
would
expect
result
better
clinic
outcom
wild
type
nonwild
type
born
use
leukotrien
inhibitor
found
increas
forc
expiratori
volum
wildtyp
asthma
patient
compar
nonwild
type
clinic
screen
polymorph
infanc
near
futur
like
genet
test
help
guid
therapi
airway
inflamm
characterist
featur
asthma
contribut
mani
hallmark
diseas
includ
airflow
obstruct
bronchial
hyperrespons
initi
remodel
classic
microscop
featur
includ
infiltr
airway
inflammatori
cell
hypertrophi
smooth
muscl
thicken
lamina
reticulari
basement
membran
persist
airway
inflamm
consid
characterist
featur
sever
mild
even
asymptomat
asthma
pattern
inflamm
vari
sever
chronic
diseas
may
also
determin
respons
patient
treatment
mani
inflammatori
cell
cytokin
chemokin
adhes
protein
contribut
airway
inflamm
asthma
one
mechan
initi
airway
inflamm
antigen
exposur
sensit
individu
result
activ
resid
cell
airway
mast
cell
recruit
inflammatori
cell
lymphocyt
neutrophil
eosinophil
airway
fig
antigen
bind
specif
ige
antibodi
bound
mast
cell
bind
activ
mast
cell
releas
preform
histamin
newli
gener
leukotrien
prostaglandin
along
transcript
numer
cytokin
histamin
prostaglandin
leukotrien
induc
bronchoconstrict
mucu
secret
mucos
edema
key
proinflammatori
cytokin
includ
regul
ige
synthesi
lymphocyt
differenti
develop
eosinophil
inflamm
mast
cell
also
produc
cytokin
proteas
includ
transform
growth
factor
tgf
fibroblast
growth
factor
tryptas
chymas
may
contribut
remodel
airway
wall
activ
myofibroblast
tlymphocyt
primari
effector
cell
asthma
coordin
mani
action
inflammatori
cell
airway
releas
cytokin
also
lymphocyt
epitheli
cell
gener
chemokin
includ
rant
eotaxin
enabl
recruit
eosinophil
airway
anoth
critic
step
process
activ
endotheli
adhes
protein
intercellular
adhes
molecul
icam
vascular
cell
adhes
molecul
vcam
protein
combin
specif
receptor
neutrophil
eosinophil
lymphocyt
reduc
flow
cell
blood
vessel
assist
cell
movement
vessel
airway
airway
inflammatori
cell
releas
variou
enzym
protein
damag
airway
epithelium
contribut
inflamm
eosinophil
consid
predomin
characterist
cell
asthma
observ
bronchoalveolar
lavag
bal
bronchial
biopsi
eosinophil
contain
sever
granul
toxic
airway
four
princip
basic
protein
major
basic
protein
mbp
eosinophil
cation
protein
ecp
eosinophil
peroxidas
epo
eosinophildriven
neurotoxin
edn
protein
associ
desquam
epithelium
asthmat
airway
enhanc
vagal
mediat
bronchoconstrict
eosinophil
also
produc
inflammatori
cytokin
growth
factor
chemokin
neutrophil
like
role
certain
subset
asthma
neutrophil
becom
activ
releas
myeloperoxidas
toxic
respiratori
epithelium
neutrophil
accumul
hallmark
patient
die
suddenli
asthma
patient
sever
corticosteroiddepend
asthma
cytokin
glycoprotein
synthes
releas
mani
cell
type
activ
cytokin
includ
interleukin
interferon
growth
factor
primari
effect
inflamm
includ
regul
ige
synthesi
mediat
eosinophil
activ
induct
cellular
adhes
molecul
mediat
transendotheli
migrat
leukocyt
primari
cytokin
airway
profil
asthma
patient
includ
granulocytemacrophag
colonystimul
factor
gmcsf
patient
allerg
asthma
increas
wherea
nonallerg
asthma
primarili
increas
lack
increas
nonallerg
asthma
like
due
lack
igemedi
respons
wherea
group
eosinophil
involv
regul
chemokin
anoth
group
molecul
contribut
asthma
inflamm
chemotact
activ
chemokin
divid
two
main
famili
chemokin
recruit
neutrophil
b
chemokin
recruit
eosinophil
mononuclear
cell
latter
includ
rant
eotaxin
work
conjunct
caus
local
tissu
migrat
eosinophil
releas
circul
rel
contribut
b
chemokin
emerg
develop
specif
antagonist
effect
variou
asthma
model
thick
airway
wall
increas
asthma
relat
diseas
sever
increas
thick
result
increas
tissu
compart
includ
smooth
muscl
epithelium
submucosa
adventitia
mucos
gland
inflammatori
edema
involv
entir
airway
particularli
submucos
layer
mark
hypertrophi
hyperplasia
submucos
gland
hyperplasia
goblet
cell
also
mani
mediat
lead
contract
bronchial
smooth
muscl
histamin
leukotrien
increas
permeabl
capillari
membran
caus
mucos
edema
chang
combin
contribut
obstruct
airway
flow
one
characterist
featur
sever
asthma
overproduct
mucu
mucu
mechan
narrow
airway
lumen
caus
obstruct
sever
asthma
tenaci
mucu
plug
caus
airway
obstruct
lead
ventilationperfus
mismatch
hypoxemia
mucu
plug
compos
mucu
serum
protein
inflammatori
cell
cellular
debri
includ
desquam
epitheli
cell
macrophag
arrang
spiral
pattern
curschmann
spiral
develop
mucu
plug
occur
sever
prolong
attack
asthma
patient
chronic
diseas
end
result
compromis
airway
lumen
impair
mucociliari
clearanc
patient
asthma
develop
irrevers
airflow
obstruct
process
label
airway
remodel
repres
injuryrepair
process
airway
tissu
remodel
occur
dysregul
attempt
tissu
repair
sever
compon
airway
remodel
identifi
includ
hypertrophi
airway
smooth
muscl
hyperplasia
mucu
gland
goblet
cell
angiogenesi
vascular
hyperplasia
collagen
deposit
fibrosi
airway
featur
appear
perman
revers
treatment
process
lead
develop
fulli
defin
question
answer
process
occur
asthma
patient
other
process
appear
control
mediat
distinct
involv
acut
inflammatori
respons
gener
presenc
growth
factor
appear
critic
lead
structur
chang
airway
tissu
airway
epithelium
like
key
regul
remodel
process
bidirect
commun
demonstr
epitheli
mesenchym
cell
system
damag
epitheli
layer
stimul
myofibroblast
prolif
respons
associ
increas
level
growth
factor
overal
transit
remodel
inflamm
suggest
new
group
mediat
action
smooth
muscl
growth
collagen
deposit
blood
vessel
prolifer
mucu
gland
hyperplasia
although
theoriz
adequ
control
inflamm
result
less
remodel
prove
clinic
current
highprior
research
subject
airway
hyperrespons
increas
airway
narrow
exposur
constrictorinduc
agent
asthma
patient
occur
exposur
chemic
physic
stimuli
allergen
chemic
stimuli
includ
cholinerg
agonist
methacholin
carbachol
also
histamin
leukotrien
prostaglandin
adenosin
physic
stimuli
includ
exercis
hyperventil
cold
dri
air
hypoton
hyperton
nebul
solut
airway
hyperrespons
demonstr
nearli
patient
symptomat
asthma
sometim
specif
trigger
need
demonstr
subject
normal
methacholin
respons
still
develop
symptomat
asthma
expos
appropri
stimuli
specif
allergen
occup
chemic
exposur
airway
hyperrespons
correl
directli
airway
inflamm
asthma
airway
hyperrespons
improv
children
adult
asthma
treat
inhal
corticosteroid
decreas
inflamm
appear
airway
hyperrespons
caus
inflammatori
structur
chang
airway
although
particular
cell
mediat
fulli
identifi
structur
chang
associ
airway
hyperrespons
includ
patchi
desquam
epithelium
thicken
reticular
collagen
layer
basement
membran
hypertrophi
hyperplasia
airway
smooth
muscl
airway
hyperrespons
howev
uniqu
asthma
posit
methacholin
challeng
test
diagnost
airway
hyperrespons
also
seen
atop
diseas
cystic
fibrosi
rhiniti
smoker
even
normal
individu
week
viral
respiratori
infect
patholog
chang
seen
fatal
asthma
gener
similar
seen
sever
asthma
signific
extent
multipl
factor
caus
excess
airway
narrow
fatal
asthma
includ
increas
product
mucu
increas
shorten
airway
smooth
muscl
alter
mechan
airway
wall
loss
inflammatori
inhibitori
factor
increas
permeabl
epitheli
damag
one
common
characterist
find
occlus
bronchial
lumen
mucu
plug
occur
airway
size
interest
calcul
content
submucu
gland
alon
caus
excess
narrow
therefor
accumul
mucu
addit
effect
smooth
muscl
shorten
caus
excess
narrow
airway
goblet
cell
hyperplasia
lead
excess
mucu
product
like
repres
repar
respons
epitheli
damag
attempt
restor
normal
protect
barrier
epitheli
damag
appear
sever
sourc
inflammatori
milieu
result
product
protein
proteas
chemic
toxic
epithelium
concomit
viral
infect
often
seen
fatal
asthma
damag
epithelium
addit
stimul
goblet
cell
hyperplasia
damag
epithelium
result
easier
access
irrit
nerv
end
enhanc
penetr
allergen
particl
loss
inactiv
proinflammatori
peptid
reduc
mucociliari
clearanc
inflammatori
pattern
fatal
asthma
variabl
eosinophil
tlymphocyt
predomin
cell
type
neutrophil
also
implic
major
role
subset
patient
fatal
asthma
edema
airway
regard
import
featur
fatal
asthma
difficult
quantifi
edema
contribut
increas
wall
thick
fatal
asthma
caus
pronounc
decreas
diamet
airway
lumen
contract
smooth
muscl
similarli
one
hallmark
sever
fatal
asthma
thicken
subepitheli
basement
membran
zone
dens
deposit
collagen
fibril
exponenti
reduc
airway
diamet
smooth
muscl
contract
studi
clinic
characterist
histopatholog
find
provid
better
understand
mechan
underli
differ
clinic
form
asthma
cystic
fibrosi
autosom
recess
diseas
frequenc
one
approxim
birth
common
present
symptom
sign
includ
persist
sinopulmonari
infect
pancreat
insuffici
failur
thrive
respiratori
symptom
includ
persist
product
cough
hyperinfl
lung
field
pulmonari
function
test
consist
obstruct
airway
diseas
howev
mani
patient
demonstr
mild
atyp
symptom
includ
wheez
clinician
remain
alert
possibl
cystic
fibrosi
even
usual
featur
present
particularli
presenc
nasal
polyp
child
alert
physician
possibl
cystic
fibrosi
sweat
chlorid
test
perform
exclud
cystic
fibrosi
even
slightest
suspicion
diseas
test
perform
diagnosi
cystic
fibrosi
major
implic
patient
bronchopulmonari
dysplasia
chronic
lung
diseas
occur
prematur
infant
character
impair
alveologenesi
lead
global
decreas
number
alveoli
gasexchang
surfac
area
occur
infrequ
infant
week
gestat
age
birth
weight
g
infant
bronchopulmonari
dysplasia
ventilatordepend
birth
respiratori
distress
syndrom
requir
surfact
therapi
howev
bronchopulmonari
dysplasia
develop
situat
respiratori
distress
syndrom
mild
absent
physic
examin
find
vari
common
find
tachypnea
retract
depend
amount
atelectasi
pulmonari
edema
crackl
expiratori
wheez
may
may
present
chest
radiograph
show
variou
find
includ
normal
low
lung
volum
diffus
hazi
due
inflamm
pulmonari
edema
atelectasi
air
trap
hyperinfl
infant
gradual
improv
first
month
initi
instabl
first
week
oxygen
supplement
gradual
wean
infant
maintain
adequ
oxygen
room
air
foreign
bodi
aspir
suspect
patient
present
sudden
onset
wheez
particularli
previou
histori
wheez
approxim
case
pediatr
foreign
bodi
aspir
occur
children
younger
year
peak
incid
year
age
commonli
aspir
foreign
bodi
children
includ
peanut
nut
seed
hardwar
piec
toy
sign
symptom
foreign
bodi
aspir
vari
accord
locat
foreign
bodi
elaps
time
sinc
event
sever
acut
event
child
present
sever
respiratori
distress
stridor
hoars
cyanosi
emerg
situat
object
usual
lodg
larynx
trachea
commonli
foreign
bodi
locat
bronchi
right
lung
left
lung
situat
less
emerg
physic
examin
find
includ
gener
wheez
local
find
focal
wheez
decreas
breath
sound
classic
triad
wheez
cough
diminish
breath
sound
present
case
patient
may
also
present
day
week
initi
aspir
situat
often
present
nonspecif
symptom
dyspnea
wheez
chronic
cough
recurr
pneumonia
care
histori
requir
inquir
initi
choke
episod
may
forgotten
histori
choke
specif
sought
found
approxim
confirm
case
plain
chest
radiograph
sometim
help
foreign
bodi
aspir
use
depend
degre
airway
obstruct
whether
object
radiopaqu
aspir
foreign
bodi
radioluc
food
limit
use
radiograph
bronchial
foreign
bodi
aspir
common
radiograph
find
hyperinfl
lung
atelectasi
mediastin
shift
pneumonia
find
seen
approxim
case
children
suggest
histori
normal
chest
radiograph
expiratori
chest
radiographi
fluoroscopi
may
help
comput
tomographi
ct
scan
magnet
reson
imag
mri
appear
limit
use
rigid
bronchoscopi
perform
foreign
bodi
suspect
although
flexibl
bronchoscopi
also
use
purpos
rigid
bronchoscopi
current
consid
procedur
choic
remov
aspir
foreign
bodi
children
tracheoesophag
fistula
common
congenit
anomali
occur
approxim
birth
typic
occur
esophag
atresia
occur
alon
htype
fistula
case
infant
tracheoesophag
fistula
esophag
atresia
symptom
develop
immedi
birth
excess
secret
choke
drool
respiratori
distress
inabl
feed
patient
htype
fistula
present
cough
choke
associ
feed
depend
size
fistula
diagnosi
delay
month
year
small
fistula
patient
histori
mild
respiratori
distress
associ
feed
recurr
episod
pneumonia
diagnosi
tracheoesophag
fistula
esophag
atresia
made
attempt
pass
cathet
stomach
confirm
coil
chest
radiograph
diagnosi
isol
tracheoesophag
fistula
difficult
sometim
confirm
upper
gastrointestin
seri
use
thicken
water
contrast
materi
often
esophag
endoscopi
bronchoscopi
requir
treatment
surgic
ligat
fistula
anastomosi
esophag
segment
prognosi
gener
good
close
followup
requir
esophag
strictur
tracheomalacia
report
complic
tracheomalacia
character
dynam
collaps
trachea
respir
result
airway
obstruct
lesion
intrathorac
caus
airway
collaps
expir
extrathorac
lesion
rare
lead
collaps
inspir
three
type
tracheomalacia
type
due
intrins
defect
cartilagin
portion
trachea
result
increas
proport
membran
trachea
result
airway
collaps
type
tracheomalacia
caus
extrins
tracheal
compress
congenit
acquir
associ
compress
cardiovascular
structur
tumor
lymph
node
mass
type
lesion
result
prolong
posit
pressur
ventil
inflammatori
process
weaken
cartilagin
support
trachea
sign
symptom
depend
locat
extent
tracheal
abnorm
patient
intrathorac
tracheomalacia
typic
present
noisi
breath
recurr
harsh
bark
crouplik
cough
comparison
extrathorac
lesion
caus
inspiratori
stridor
symptom
may
increas
infant
supin
wheez
present
birth
usual
becom
appar
first
month
life
wheez
becom
promin
upper
respiratori
tract
infect
activ
although
chest
radiograph
often
normal
help
assess
mediastin
mass
cardiomegali
chang
airway
calib
fluoroscopi
sometim
establish
diagnosi
definit
diagnosi
usual
made
bronchoscopi
observ
tracheal
collaps
expir
ct
mri
may
help
defin
extent
lesion
affect
infant
spontan
improv
month
age
howev
patient
remain
symptomat
adulthood
exercis
intoler
may
seen
adult
sever
instanc
treatment
includ
posit
pressur
ventilatori
support
tracheal
surgeri
placement
tracheal
stent
laryng
web
rare
congenit
abnorm
caus
failur
resorpt
epitheli
layer
cover
laryng
open
failur
resorpt
vocal
fold
incomplet
separ
caus
obstruct
web
occur
anywher
along
anterior
posterior
larynx
also
occur
trauma
airway
intub
injuri
patient
laryng
web
usual
present
infanc
respiratori
distress
unusu
cri
milder
diseas
symptom
may
occur
later
includ
hoars
weak
voic
breathi
vari
degre
dyspnea
stridor
depend
extent
obstruct
diagnosi
made
visual
web
extent
surgic
treatment
requir
depend
area
lesion
rang
simpl
lysi
web
laryng
reconstruct
bronchiol
gener
term
use
describ
presenc
nonspecif
inflammatori
respons
small
airway
term
confus
describ
clinic
syndrom
constel
histolog
abnorm
may
occur
number
variou
process
publish
report
bronchiol
often
tissu
confirm
diseas
explain
mani
uncertainti
epidemiolog
pathophysiolog
therapi
condit
clinic
syndrom
associ
bronchiol
includ
inhal
injuri
druginduc
reaction
associ
connect
tissu
diseas
idiopath
commonli
infect
children
bronchiol
refer
infecti
asthma
wheezi
bronchiti
diagnosi
bronchiol
base
typic
histori
result
physic
examin
key
find
infecti
bronchiol
includ
intermitt
fever
runni
nose
cough
tachypnea
abdomin
pain
crackl
wheez
presenc
sever
find
shown
distinguish
reliabl
among
viral
bacteri
atyp
organ
respiratori
syncyti
viru
rsv
common
viral
caus
bronchiol
children
younger
year
laboratori
test
includ
chest
radiographi
rapid
viral
panel
cultur
complet
blood
count
cbc
consid
low
util
evalu
children
mild
airway
diseas
report
clear
benefit
test
children
moder
sever
airway
diseas
chest
radiograph
may
normal
although
instanc
hyperinfl
peribronchi
thicken
atelectasi
may
present
although
asthma
bronchiol
share
clinic
manifest
possibl
pathogenes
import
tri
distinguish
basi
past
histori
current
present
mani
children
bronchiol
develop
asthma
may
inappropri
label
particularli
first
episod
risk
factor
identifi
wheez
viral
infect
infanc
earli
childhood
includ
matern
smoke
matern
histori
asthma
elev
ige
level
environment
histori
overal
review
system
help
distinguish
entiti
thu
allow
implement
avoid
techniqu
prevent
futur
exacerb
also
wheez
child
younger
year
risk
asthma
increas
one
major
criterion
two
minor
criteria
met
major
criteria
parent
asthma
eczemaminor
criteria
allerg
rhiniti
eosinophilia
wheez
apart
viral
upper
respiratori
tract
ill
children
younger
year
frequent
respond
vigor
inhal
inject
bronchodil
pure
infecti
set
although
subset
show
improv
therapeut
trial
consid
vascular
ring
abnorm
caus
development
failur
part
pair
aortic
arch
embryon
life
may
result
compress
trachea
esophagu
symptomat
vascular
ring
usual
diagnos
earli
life
delay
first
appear
symptom
time
diagnosi
signific
diagnosi
usual
made
first
year
life
inspiratori
stridor
wheez
dyspnea
promin
case
vascular
ring
respiratori
symptom
recurr
respiratori
tract
infect
cough
may
associ
vascular
ring
persist
symptom
rais
question
possibl
vascular
ring
clue
vascular
ring
chest
radiographi
includ
rightsid
aortic
arch
tracheal
compress
howev
find
often
absent
esophographi
sensit
show
doubl
esophag
impress
frontal
view
associ
posterior
notch
side
view
studi
perform
better
defin
anatomi
includ
bronchoscopi
ct
mri
angiographi
treatment
symptomat
vascular
ring
surgic
correct
immunodefici
present
myriad
way
condit
may
confus
asthma
particularli
earlier
stage
humor
immun
defici
result
impair
antibodi
product
intrins
bcell
defect
dysfunct
interact
b
tcell
although
tcell
defect
underli
diseas
cellular
immun
larg
intact
result
antibodi
defici
humor
immun
defici
lead
recurr
upper
lower
respiratori
tract
infect
encapsul
bacteria
streptococcu
pneumonia
haemophilu
influenza
common
humor
primari
immunodefici
iga
defici
xlink
agammaglobulinemia
common
variabl
immunodefici
igadefici
individu
nearli
asymptomat
symptomat
often
concurr
immunodefici
xlink
agammaglobulinemia
common
variabl
immunodefici
manifest
childhood
adulthood
although
xlink
agammaglobulinemia
typic
becom
manifest
month
age
evalu
patient
recurr
sinopulmonari
infect
includ
iga
igm
igg
immunoglobulin
level
igg
markedli
decreas
xlink
agammaglobulinemia
common
variabl
immunodefici
condit
treatment
consist
immunoglobulin
replac
immunoglobulin
replac
therapi
iga
defici
patient
often
antiiga
antibodi
risk
anaphylact
reaction
receiv
blood
product
bronchiol
obliteran
rare
diseas
caus
epitheli
injuri
lower
respiratori
tract
result
obstruct
lower
airway
idiopath
occur
infecti
chemic
immunolog
injuri
patient
usual
present
tachypnea
dyspnea
cough
wheez
unrespons
bronchodil
therapi
physic
examin
show
diffus
wheez
crackl
chest
radiograph
typic
show
diffus
interstiti
infiltr
atelectasi
pulmonari
function
test
show
airway
obstruct
without
respons
bronchodil
chronic
obstruct
pulmonari
diseas
copd
character
airflow
limit
oppos
typic
asthma
fulli
revers
airflow
limit
usual
progress
associ
abnorm
inflammatori
respons
lung
noxiou
particl
gase
primarili
caus
cigarett
smoke
diagnosi
copd
consid
patient
cough
sputum
product
dyspnea
histori
exposur
risk
factor
primarili
smoke
diseas
diagnosi
requir
spirometri
decreas
vital
capac
fvc
ratio
establish
obstruct
process
alon
though
definit
pattern
seen
asthma
key
differenti
featur
clinic
present
lack
revers
treatment
exposur
primarili
smoke
histori
diffus
capac
carbon
monoxid
dlco
pulmonari
function
test
tabl
dlco
normal
increas
asthma
decreas
copd
patient
asthma
distinguish
copd
subset
patient
may
asthma
copd
manag
patient
similar
asthma
primari
treatment
copd
consist
bronchodil
glucocorticoid
oxygen
therapi
bronchodil
commonli
use
anticholinerg
drug
less
commonli
methylxanthin
medic
use
combin
short
longact
form
exampl
patient
stage
copd
may
use
longact
anticholinerg
agent
conjunct
longact
agent
daili
ad
shortact
anticholinerg
need
effect
glucocorticoid
copd
less
dramat
asthma
studi
inhal
corticosteroid
caus
small
increas
small
reduct
bronchial
reactiv
stabl
copd
reduct
copd
exacerb
studi
signific
chang
note
current
trial
inhal
corticosteroid
institut
stage
copd
continu
clinic
improv
note
period
withdrawn
clinic
improv
note
although
neither
chronic
bronchiti
emphysema
requir
definit
copd
term
often
use
describ
patient
copd
chronic
bronchiti
tradit
label
blue
bloater
clinic
diagnosi
defin
presenc
chronic
product
cough
month
two
success
year
emphysema
tradit
label
pink
puffer
patholog
term
describ
abnorm
perman
dilat
airspac
distal
termin
bronchiol
result
poor
oxygen
diffus
pulmonari
vasculatur
patient
copd
without
fall
two
categori
obstruct
primari
manifest
treatment
group
essenti
copd
vocal
cord
paralysi
caus
respiratori
symptom
vari
extent
paralysi
paresi
versu
complet
paralysi
exact
locat
affect
cord
whether
unilater
bilater
unilater
vocal
cord
paralysi
associ
breathi
voic
ineffect
cough
dysphagia
aspir
sign
symptom
sought
particularli
voic
compon
symptom
paralysi
caus
primarili
injuri
inflamm
vagu
recurr
laryng
nerv
common
caus
includ
surgeri
procedur
involv
thyroid
gland
carotid
arteri
neck
chest
base
skull
caus
includ
tumor
trauma
aneurysm
neural
disord
howev
bilater
vocal
cord
paralysi
often
associ
preserv
voic
respiratori
aspir
sign
bilater
vocal
cord
paralysi
usual
caus
bilater
thyroid
surgeri
also
caus
neurolog
event
postintub
tracheal
lesion
common
caus
upper
airway
obstruct
repres
princip
indic
tracheal
resect
reconstruct
surgeri
patient
subglott
stenosi
injuri
caus
cuffinduc
pressur
necrosi
subsequ
format
granuloma
fibrot
tissu
main
risk
factor
develop
lesion
prolong
intub
obstruct
becom
manifest
day
year
intub
therefor
upper
airway
obstruct
suspect
imper
inquir
previou
intub
histori
sever
system
diseas
shown
caus
upper
airway
obstruct
wegen
granulomatosi
classic
character
necrot
granulomat
vascul
upper
lower
airway
case
involv
kidney
nation
institut
health
studi
patient
wegen
granulomatosi
tracheal
stenosi
present
manifest
tracheal
stenosi
also
report
sarcoidosi
amyloidosi
idiopath
subglott
stenosi
diagnosi
exclus
clear
whether
group
repres
distinctli
separ
group
collect
differ
system
ill
identifi
gener
appear
two
group
patient
mild
diseas
respond
well
laser
incis
dilat
dens
complex
scar
requir
resect
reconstruct
disproportion
number
femal
afflict
signific
unclear
normal
tracheal
diamet
rang
mm
narrow
upper
airway
dyspnea
exert
typic
first
symptom
becom
manifest
airway
diamet
narrow
mm
symptom
rest
decreas
peak
flow
read
occur
mm
pulmonari
function
test
classic
show
flatten
inspiratori
expiratori
loop
fix
upper
airway
obstruct
relaps
polychondr
present
variou
way
depend
sever
organ
system
involv
auricular
involv
common
featur
eventu
appear
approxim
patient
area
involv
includ
eye
nose
airway
cardiovascular
system
skin
joint
kidney
nervou
system
primari
airway
manifest
relaps
polychondr
includ
glottic
subglott
laryng
tracheobronchi
inflamm
lumin
encroach
fibrosisinduc
lumin
contractur
loss
structur
cartilagin
support
result
laryng
collaps
forc
inspir
tracheal
collaps
expir
symptom
includ
hoars
aphonia
wheez
inspiratori
stridor
nonproduct
cough
dyspnea
onset
like
fifth
sixth
decad
although
age
group
affect
relaps
polychondr
may
coexist
variou
vasculitid
autoimmun
ill
physic
examin
find
depend
organ
involv
classic
find
includ
diffus
violac
erythemat
appear
cartilagecontain
area
auricl
saddlenos
nasal
deform
test
diagnost
specif
relaps
polychondr
diagnosi
establish
clinic
find
support
laboratori
data
biopsi
involv
cartilagin
site
pulmonari
function
test
may
show
vari
degre
inspiratori
expiratori
obstruct
mark
expiratori
obstruct
correl
well
bronchoscop
abnorm
upper
airway
foreign
bodi
aspir
common
children
adult
approxim
recogn
case
occur
patient
older
year
adult
natur
foreign
bodi
highli
variabl
neurolog
disord
syncop
alcohol
sed
abus
predispos
foreign
bodi
aspir
acut
present
adult
rare
subacut
chronic
present
initi
choke
episod
often
recal
cough
seen
approxim
case
associ
symptom
includ
fever
hemoptysi
chest
pain
wheez
dyspnea
present
time
diagnosi
frequent
overlook
unless
patient
report
queri
choke
episod
radiograph
radiopaqu
foreign
bodi
seen
routin
imag
unilater
hyperinfl
occur
common
pediatr
adult
popul
fiberopt
bronchoscopi
diagnost
procedur
choic
adult
although
rigid
bronchoscopi
may
requir
extract
myxoma
common
primari
cardiac
tumor
clinic
manifest
depend
anatom
locat
tumor
approxim
myxoma
origin
left
atrium
major
other
found
right
atrium
tumor
vari
wide
size
rang
cm
diamet
common
respiratori
symptom
dyspnea
cough
associ
cardiovascular
sign
symptom
often
includ
orthopnea
paroxysm
nocturn
dyspnea
pulmonari
edema
edema
fatigu
symptom
may
worsen
certain
bodi
posit
locat
tumor
atrium
physic
examin
find
addit
evid
right
heart
left
heart
dysfunct
includ
diastol
murmur
evid
embol
echocardiographi
test
choic
initi
evalu
cardiac
mri
ct
also
perform
help
distinguish
type
tumor
studi
provid
background
regard
need
type
surgic
intervent
mitral
valv
prolaps
common
disord
occur
popul
caus
primari
mitral
valv
prolaps
unknown
classic
auscultatori
featur
midsystol
click
multipl
click
sometim
follow
midsystol
late
systol
murmur
apex
sever
nonspecif
symptom
associ
mitral
valv
prolaps
term
mitral
valv
syndrom
includ
dyspnea
exercis
intoler
panic
anxieti
palpit
numb
control
clinic
studi
suggest
patient
mitral
valv
prolaps
control
subject
equal
symptomat
although
autonom
neuroendocrin
dysfunct
may
underli
symptom
associ
mitral
valv
prolaps
congest
heart
failur
may
manifest
symptom
similar
asthma
wheez
worsen
respiratori
symptom
night
physic
activ
main
point
awar
possibl
congest
heart
failur
physic
examin
often
provid
diagnosi
major
find
includ
elev
jugular
venou
puls
crackl
lung
examin
lower
extrem
edema
cardiac
examin
may
also
show
abnorm
rhythm
soft
heart
sound
murmur
vocal
cord
dysfunct
also
known
function
upper
airway
obstruct
episod
paroxysm
laryngospasm
paradox
vocal
cord
movement
entiti
without
specif
organ
caus
may
mimic
asthma
organ
upper
airway
obstruct
normal
respiratori
cycl
vocal
cord
abduct
inspir
expir
allow
maxim
airflow
vocal
cord
dysfunct
vocal
cord
inappropri
adduct
inspir
function
airway
obstruct
result
mark
inspiratori
stridor
mistaken
asthmat
wheez
attack
laryngoscopi
show
paradox
inspiratori
adduct
anterior
vocal
cord
posterior
diamondshap
glottic
gap
time
spirometri
demonstr
flatten
inspiratori
flowvolum
loop
normal
expiratori
flowvolum
loop
howev
patient
asymptomat
result
laryngoscopi
spirometri
typic
normal
vocal
cord
dysfunct
appear
psychogen
natur
patient
consid
maling
intent
produc
symptom
current
thought
repres
convers
disord
associ
condit
depress
patient
may
present
signific
respiratori
distress
dramat
inspiratori
stridor
physic
examin
harsh
breath
sound
loudest
sternal
notch
less
audibl
chest
wall
suspicion
asthma
patient
typic
receiv
treatment
highdos
glucocorticoid
agonist
fail
reliev
symptom
condit
patient
often
label
refractori
asthma
arteri
blood
gase
normal
patient
symptomat
asymptomat
import
note
vocal
cord
dysfunct
coexist
true
asthma
asthma
patient
may
degre
vocal
cord
dysfunct
clue
help
distinguish
vocal
cord
dysfunct
asthma
includ
follow
minim
respons
aggress
asthma
treatmentflatten
inspiratori
flowvolum
loop
symptomaticstridor
physic
examin
symptomaticnorm
arteri
blood
ga
measur
sever
attack
vocal
cord
dysfunct
difficult
treat
case
diagnosi
often
delay
difficult
taper
discontinu
longstand
medic
difficult
patient
accept
diagnosi
nonorgan
disord
welldefin
treatment
protocol
studi
publish
effect
psychodynam
psychopharmacolog
treatment
success
report
speech
therapi
use
breath
techniqu
voic
neck
relax
exercis
elimin
symptom
onset
patient
often
postnas
drainag
gastroesophag
reflux
diseas
gerd
contribut
vocal
cord
dysfunct
manag
disord
help
decreas
dysfunct
although
cystic
fibrosi
commonli
thought
childhood
diseas
uncommon
initi
diagnosi
made
adult
year
respiratori
manifest
includ
persist
product
cough
hyperinfl
lung
seen
chest
film
pulmonari
function
test
consist
obstruct
process
concomit
sinu
diseas
advanc
diseas
bronchiectasi
appear
sweat
chlorid
test
initi
test
choic
adult
result
sometim
equivoc
molecular
diagnosi
usual
made
direct
mutat
analysi
specif
known
mutat
cystic
fibrosi
transmembran
conduct
regul
cftr
gene
bronchial
carcinoid
tumor
rare
compris
less
primari
tumor
lung
occur
age
mean
age
year
clinic
present
usual
consist
recurr
pneumon
cough
hemoptysi
interest
dyspnea
typic
symptom
associ
carcinoid
syndrom
flush
diarrhea
rare
fiberopt
bronchoscopi
tumor
biopsi
usual
diagnost
procedur
surviv
rate
pulmonari
function
test
use
detect
airway
expiratori
flow
obstruct
airway
hyperrespons
pulmonari
function
test
two
compon
spirometri
plethysmographi
patient
asthma
evalu
asthma
spirometri
spirometri
measur
maxim
volum
air
forcibl
exhal
point
maxim
inhal
fvc
volum
air
exhal
first
second
maneuv
flowvolum
curv
gener
plot
flow
rate
l
yaxi
versu
lung
volum
l
xaxi
expiratori
flow
obstruct
indic
decreas
decreas
ratio
compar
predict
valu
base
age
height
sex
race
symptomat
asthma
typic
decreas
wherea
fvc
remain
rel
normal
airway
obstruct
result
characterist
appear
flowvolum
loop
scoop
appear
expiratori
loop
fig
chang
howev
specif
asthma
also
seen
copd
spirometri
gener
perform
children
older
year
although
mani
children
perform
maneuv
age
year
younger
children
manag
decis
initi
adjust
treatment
base
primarili
frequenc
sever
past
exacerb
symptom
present
spirometri
use
guid
assess
respons
treatment
anoth
compon
spirometri
determin
revers
indic
bronchodil
respons
agonist
albuterol
bronchodil
administ
often
improv
signific
improv
bronchodil
administ
defin
american
thorac
societi
increas
repres
least
increas
volum
respons
suggest
diagnosi
asthma
patient
asthma
exhibit
signific
bronchodil
respons
mark
underli
inflamm
patient
often
low
baselin
may
requir
antiinflammatori
treatment
demonstr
revers
methacholin
bronchoprovoc
test
perform
measur
airway
hyperrespons
methacholin
cholinerg
agonist
stimul
muscarin
receptor
airway
smooth
muscl
produc
bronchoconstrict
patient
asthma
airway
smooth
muscl
sensit
methacholin
result
bronchoconstrict
lower
dosag
thu
differenti
patient
asthma
without
asthma
although
differ
protocol
use
methacholin
challeng
result
often
present
provoc
concentr
result
decreas
one
method
perform
methacholin
challeng
use
methacholin
solut
inhal
two
millilit
solut
place
nebul
patient
instruct
take
one
deep
inhal
follow
repeat
spirometri
decreas
less
four
breath
methacholin
administ
decreas
test
posit
shortact
administ
ensur
return
toward
baselin
valu
type
test
perform
patient
known
asthma
patient
sensit
develop
sever
bronchospasm
test
perform
patient
normal
baselin
spirometri
diagnosi
asthma
question
falseposit
methacholin
challeng
seen
allerg
rhiniti
cystic
fibrosi
copd
congest
heart
failur
tobacco
use
upper
respiratori
tract
infect
pulmonari
function
test
also
use
diagnos
upper
airway
obstruct
pattern
obstruct
caus
upper
airway
lesion
determin
level
airway
obstruct
occur
physiolog
laryngotrach
airway
divid
two
level
intrathorac
extrathorac
intrathorac
airway
surround
pleural
pressur
extrathorac
airway
atmospher
pressur
obstruct
caus
lesion
chang
respiratori
cycl
call
variabl
lesion
variabl
extrathorac
obstruct
vocal
cord
paralysi
vocal
cord
dysfunct
character
increas
obstruct
inspir
increas
due
neg
pressur
within
airway
compar
posit
atmospher
pressur
around
airway
inspir
expir
howev
mark
posit
pressur
within
airway
decreas
obstruct
expiratori
curv
may
normal
fig
convers
variabl
intrathorac
obstruct
usual
due
tumor
caus
increas
obstruct
expir
occur
posit
pleural
pressur
expir
caus
compress
airway
site
lesion
inspir
neg
pleural
pressur
lessen
obstruct
allow
normal
inspiratori
loop
fig
fix
obstruct
airway
diamet
chang
inspir
expir
decreas
airflow
site
obstruct
repres
plateau
seen
expiratori
inspiratori
curv
fig
dlco
measur
abil
lung
transfer
ga
inhal
air
red
blood
cell
pulmonari
capillari
help
distinguish
asthma
emphysema
particularli
patient
risk
ill
smoker
older
patient
asthma
dlco
typic
normal
increas
wherea
emphysema
pulmonari
parenchym
diseas
ga
exchang
membran
impair
dlco
decreas
smoker
airway
obstruct
normal
dlco
valu
usual
chronic
obstruct
bronchiti
emphysema
peak
flow
measur
simpl
inexpens
way
monitor
airflow
offic
home
maneuv
patient
expir
forc
peak
flow
meter
hollow
tube
measur
peak
expiratori
flow
rate
pefr
liter
per
second
although
pefr
accur
spirometri
correl
well
presenc
bronchospasm
good
estim
sever
asthma
particularli
help
moderatetosever
persist
asthma
decreas
awar
asthma
symptom
baselin
measur
obtain
compar
futur
read
baselin
valu
obtain
patient
feel
well
period
maxim
asthma
therapi
repres
person
best
monitor
perform
schedul
need
basi
depend
patient
asthma
histori
clinician
provid
clear
instruct
patient
follow
pefr
begin
decreas
outlin
patient
asthma
action
plan
exampl
asthma
action
plan
approxim
normal
valu
pefr
provid
tabl
respect
examin
sputum
eosinophil
noninvas
way
measur
airway
inflamm
differ
induct
process
techniqu
use
patient
typic
sputum
induct
aerosol
hyperton
salin
way
nebul
patient
cough
sputum
steril
contain
process
stain
obtain
total
cell
count
differenti
cell
count
analysi
sputum
eosinophil
provid
result
compar
analysi
specimen
obtain
bronchoscopi
mild
sever
asthma
sputum
eosinophil
increas
exacerb
increas
baselin
sputum
eosinophil
count
predict
exacerb
withdraw
corticosteroid
therapi
recent
studi
use
sputum
eosinophil
count
regul
dosag
antiinflammatori
agent
patient
moder
sever
asthma
approach
result
significantli
fewer
exacerb
fewer
hospit
admiss
guidelinebas
clinic
symptom
spirometri
group
similar
corticosteroid
dose
suggest
measur
sputum
eosinophil
benefici
select
appropri
amount
antiinflammatori
medic
requir
control
asthma
current
procedur
wide
avail
consid
safe
perform
control
environ
also
potenti
import
diagnos
monitor
asthma
exhal
nitric
oxid
studi
anoth
noninvas
measur
airway
inflamm
increas
acut
exacerb
loss
asthma
control
fraction
nitric
oxid
exhal
air
increas
proport
inflamm
bronchial
wall
induc
sputum
eosinophilia
airway
hyperrespons
increas
exhal
nitric
oxid
associ
deterior
asthma
control
exhal
nitric
oxid
level
decreas
dosedepend
manner
antiinflammatori
treatment
initi
studi
shown
use
exhal
nitric
oxid
measur
perform
regularli
patient
moder
asthma
result
lower
mainten
dose
inhal
corticosteroid
need
control
asthma
compar
use
doseadjust
strategi
base
convent
guidelin
exhal
nitric
oxid
propos
diagnost
tool
asthma
baselin
level
exhal
nitric
oxid
vari
significantli
age
sex
smoke
infect
allerg
rhiniti
genet
polymorph
nitric
oxid
synthetas
gene
therefor
use
exhal
nitric
oxid
may
monitor
asthma
control
guid
therapi
predict
respons
corticosteroid
therapi
oppos
make
diagnosi
allerg
asthma
caus
inhal
specif
airborn
allergen
trigger
igemedi
reaction
allerg
asthma
impli
tempor
relationship
allergen
exposur
subsequ
respiratori
symptom
respiratori
symptom
develop
within
minut
hour
allergen
exposur
allerg
asthma
occur
commonli
age
year
also
present
older
popul
estim
patient
persist
asthma
compon
allerg
asthma
common
allergen
associ
allerg
asthma
includ
tree
grass
weed
pollen
mold
dust
mite
anim
dander
cockroach
diagnosi
allerg
asthma
suspect
sign
symptom
asthma
correl
close
local
pattern
pollen
mold
releas
perenni
symptom
asthma
present
tempor
relationship
may
obviou
continu
allergen
exposur
potenti
caus
perenni
allerg
asthma
includ
anim
dander
dust
mite
cockroach
depend
climat
pollen
mold
nonallerg
asthma
igemedi
sensit
present
nonallerg
asthma
occur
age
like
occur
patient
younger
year
older
year
result
skin
prick
test
vitro
allergen
test
neg
allergen
trigger
worsen
symptom
major
trigger
seem
upper
respiratori
tract
infect
gerd
irrit
addit
underli
inflamm
wax
wane
without
obviou
trigger
respiratori
inflamm
ige
mediat
still
primarili
eosinophil
nonallerg
asthma
gener
appear
sever
progress
cours
allerg
asthma
particularli
onset
late
life
requir
aggress
treatment
term
mix
asthma
refer
presenc
allerg
nonallerg
asthma
like
repres
major
asthma
patient
typic
exampl
patient
allerg
asthma
due
tree
pollen
flare
asthma
winter
upper
respiratori
tract
infect
exampl
includ
patient
daili
persist
asthma
posit
skin
test
correl
perenni
asthma
symptom
skin
test
posit
tree
neg
dust
mite
dog
cat
mold
aspirininduc
asthma
repres
small
subset
asthma
patient
patient
underli
asthma
nasal
polyposi
chronic
rhinosinus
develop
respiratori
sign
symptom
use
aspirin
nonsteroid
antiinflammatori
drug
nsaid
reaction
class
effect
respiratori
symptom
produc
use
cyclooxygenas
cox
inhibitor
includ
aspirin
ibuprofen
naproxen
respiratori
reaction
consist
rhinorrhea
nasal
congest
dyspnea
wheez
typic
occur
within
minut
h
ingest
interest
patient
typic
nonallerg
asthma
group
discuss
detail
medicationexacerb
asthma
section
chapter
rhinosinus
chap
sever
asthma
gener
consid
function
intens
diseas
howev
difficult
easili
defin
asthma
sever
vari
time
two
primari
measur
use
defin
asthma
sever
current
impair
futur
risk
two
measur
correl
perfectli
need
consid
adequ
address
diseas
sever
compound
variabl
use
tri
defin
asthma
sever
measur
use
defin
asthma
control
respons
asthma
treatment
also
studi
suggest
measur
health
care
use
import
addit
tradit
measur
asthma
sever
consid
american
thorac
societi
sponsor
expert
workshop
develop
consensu
definit
sever
asthma
would
appli
initi
evalu
also
patient
receiv
treatment
asthma
definit
american
thorac
societi
base
combin
major
minor
criteria
aim
identifi
subject
inadequ
control
despit
treatment
corticosteroid
accord
definit
subject
sever
asthma
must
meet
one
two
major
criteria
use
highdos
inhal
corticosteroid
requir
frequent
oral
corticosteroid
use
year
also
two
seven
minor
criteria
must
met
use
addit
control
medic
besid
inhal
corticosteroid
presenc
daili
symptom
requir
rescu
inhal
reduc
lung
function
predict
diurnal
pef
variabl
one
urgent
care
asthma
visit
per
year
recurr
exacerb
requir
oral
corticosteroid
per
year
clinic
deterior
corticosteroid
withdraw
histori
nearfat
asthma
event
tabl
current
impair
asthma
evalu
frequenc
intens
symptom
function
limit
patient
experienc
goal
achiev
minim
chronic
symptom
includ
nocturn
awaken
minim
need
acut
rescu
therapi
inhal
establish
normal
lifestyl
limit
activ
includ
exercis
normal
pulmonari
function
nation
asthma
educ
prevent
program
naepp
sponsor
nation
institut
health
publish
comprehens
guidelin
classifi
asthma
sever
mild
intermitt
mild
moder
sever
persist
asthma
basi
symptom
pulmonari
function
find
patient
mild
intermitt
asthma
experi
symptom
twice
weekli
normal
nearnorm
spirometri
pefr
patient
symptom
day
week
classifi
persist
asthma
degre
asthma
mild
moder
sever
depend
daili
symptom
nighttim
symptom
frequenc
exacerb
peak
flow
rate
spirometri
read
releas
new
inform
develop
new
therapi
updat
naepp
guidelin
releas
public
comment
februari
complet
updat
releas
late
one
signific
new
concept
differenti
asthma
sever
control
incorpor
area
relat
risk
impair
sever
assess
perform
initi
therapi
control
assess
perform
adjust
therapi
separ
two
concept
dispel
common
mispercept
wellcontrol
asthma
synonym
mild
asthma
poorli
control
asthma
synonym
sever
asthma
classif
asthma
accord
sever
children
age
children
age
older
year
accord
new
guidelin
shown
tabl
character
sever
critic
outlin
initi
treatment
plan
see
particularli
import
separ
patient
mild
intermitt
asthma
mild
persist
asthma
mild
persist
asthma
daili
antiinflammatori
medic
recommend
wherea
mild
intermitt
asthma
requir
primarili
shortact
use
need
futur
risk
also
critic
defin
asthma
sever
thu
outlin
overal
manag
plan
futur
risk
consid
likelihood
futur
asthma
exacerb
import
exacerb
account
loss
time
work
school
decreas
qualiti
life
much
cost
asthma
care
primari
futur
risk
involv
asthma
progress
loss
pulmonari
function
contrari
previou
belief
asthma
alway
total
revers
process
sever
irrevers
airflow
obstruct
acceler
loss
pulmonari
function
remodel
tissu
element
airway
wall
found
chronic
never
smoker
asthma
patient
futur
risk
one
best
assess
asthma
exacerb
strongest
predictor
risk
histori
previou
exacerb
result
emerg
depart
visit
hospit
intub
also
assess
current
sever
regard
increas
day
nighttim
symptom
function
impair
frequent
use
rescu
therapi
indic
increas
risk
exacerb
futur
howev
patient
minim
symptom
long
period
prone
sudden
sever
attack
therefor
patient
current
minim
symptom
past
histori
sever
exacerb
would
consid
sever
form
asthma
patient
without
histori
sever
exacerb
identifi
possibl
marker
risk
exacerb
studi
intens
decreas
shown
relat
increas
risk
exacerb
measur
bronchial
reactiv
exampl
methacholin
also
shown
predict
exacerb
patient
receiv
treatment
inhal
corticosteroid
dose
reduc
bronchial
reactiv
found
fewer
asthma
exacerb
treat
regularli
marker
airway
inflamm
sputum
eosinophil
exhal
nitric
oxid
also
measur
use
primari
paramet
chang
dosag
inhal
corticosteroid
treatment
fashion
shown
decreas
asthma
exacerb
howev
effect
inhal
corticosteroid
dose
variou
mean
prevent
progress
loss
pulmonari
function
clear
current
prospect
studi
shown
earli
treatment
inhal
corticosteroid
despit
prevent
exacerb
prevent
progress
asthma
sever
form
possibl
ultim
answer
question
inhal
corticosteroid
alter
natur
cours
asthma
answer
despit
lack
clariti
imper
prescrib
effect
treatment
prescrib
earli
recent
byrn
et
al
shown
daili
lowdos
antiinflammatori
treatment
patient
recent
onset
persist
asthma
decreas
loss
lung
function
time
corrobor
earlier
work
agertoft
pederson
haahtela
perhap
marker
inflamm
novel
marker
remodel
help
futur
assess
risk
thu
help
defin
sever
diseas
clearli
patient
current
symptom
measur
sever
simpl
method
assess
current
impair
avail
futur
risk
histori
exacerb
spirometri
amount
medic
requir
control
symptom
also
contribut
significantli
area
need
address
initi
evalu
sever
asthma
fluctuat
time
repeat
assess
requir
summar
follow
inform
obtain
initi
evalu
posit
answer
risk
assess
portion
point
increas
sever
current
impairmentsymptomsnighttim
awakeningsne
rescu
medicationnumb
workschool
day
missed
particip
desir
activitieslung
function
spirometri
peak
flow
risk
assessmentamount
sever
airflow
obstruct
spirometryamount
persist
airflow
obstruct
despit
maxim
pharmacotherapyhistori
two
emerg
depart
visit
hospit
asthma
past
yearhistori
intub
intens
care
unit
admiss
asthma
allergen
exposur
affect
asthma
two
critic
way
common
precipit
asthmat
symptom
incept
asthma
chronic
airway
inflamm
airborn
allergen
dust
mite
pet
mold
tree
grass
weed
oppos
food
allergen
contribut
importantli
chronic
asthma
format
ige
antibodi
airborn
allergen
usual
occur
age
year
therefor
aeroallergeninduc
asthma
uncommon
time
allergen
highest
preval
involv
asthma
later
childhood
adolesc
peak
second
decad
life
airborn
allergeninduc
asthma
occur
throughout
adulthood
howev
preval
decreas
increas
age
indoor
allergen
particularli
cockroach
cat
dust
mite
clearli
role
asthma
provoc
appear
role
asthma
incept
decreas
constant
exposur
allergen
environment
modif
diminish
primari
trigger
chronic
allerg
inflammatori
respons
may
result
mark
relief
symptom
asthma
rhiniti
reduct
airway
hyperreact
time
aeroallergen
import
allerg
rhiniti
also
contribut
asthma
exacerb
one
aeroallergen
particular
appear
trigger
sever
asthma
exacerb
alternaria
alternata
alternaria
implic
risk
factor
sudden
respiratori
arrest
adolesc
young
adult
asthma
tree
grass
weed
pollen
also
trigger
season
asthma
pattern
often
associ
upper
respiratori
tract
symptom
although
food
allergi
trigger
bronchospasm
quit
unusu
food
trigger
bronchospasm
without
concomit
symptom
typic
skin
gastrointestin
manifest
present
occur
within
h
eat
food
allergen
like
allergen
infect
affect
asthma
precipit
acut
attack
role
asthma
incept
virus
chlamydia
spp
mycoplasma
spp
implic
pathogenesi
asthma
virus
particularli
rsv
associ
incept
asthma
phenotyp
viru
ubiquit
nearli
children
infect
age
year
addit
genet
environment
sequenti
development
factor
must
contribut
linkag
asthma
children
persist
symptom
asthma
develop
asthma
rsv
infect
usual
risk
factor
matern
histori
asthma
increas
ige
level
precis
rsv
infect
pathogen
induc
asthma
establish
chlamydia
mycoplasma
spp
atyp
bacteria
associ
ciliari
dysfunct
epitheli
damag
airway
cell
presenc
airway
associ
chronic
asthma
although
presenc
provid
causal
link
asthma
macrolid
treatment
patient
chronic
asthma
without
presenc
bacteria
produc
improv
bacteria
larger
definit
studi
need
determin
whether
antibiot
treatment
patient
chronic
asthma
known
infect
chlamydia
mycoplasma
spp
alter
cours
diseas
patient
establish
asthma
viral
upper
respiratori
tract
infect
import
produc
acut
exacerb
airway
obstruct
increas
airway
hyperreact
follow
respiratori
viral
infect
usual
occur
within
h
cold
symptom
persist
least
week
possibl
mechan
includ
direct
epitheli
damag
product
virusspecif
ige
antibodi
increas
product
ige
antibodi
specif
antigen
upregul
inflammatori
mediat
releas
rhinoviru
common
cold
viru
frequent
caus
exacerb
virus
includ
metapneumoviru
parainfluenza
rsv
influenza
coronaviru
also
implic
symptom
includ
mark
wheez
short
breath
prolong
cough
typic
spasmod
wors
night
viral
upper
respiratori
tract
infect
common
provocateur
asthma
children
particularli
winter
month
asthma
flare
time
resist
standard
therapi
inhal
inhal
corticosteroid
oral
corticosteroid
may
requir
shown
decreas
hospit
viralinduc
asthma
exacerb
mycoplasma
pneumonia
chlamydia
pneumonia
commonli
associ
sever
exacerb
microb
caus
children
asthma
exacerb
requir
hospit
howev
infect
may
potenti
actual
prevent
develop
respiratori
tract
diseas
includ
asthma
hygien
hypothesi
purport
increas
number
infect
particularli
earli
childhood
may
decreas
develop
allerg
sensit
asthma
base
find
lower
rate
asthma
allerg
diseas
found
children
rais
farm
attend
day
care
first
month
life
older
sibl
thought
higher
exposur
infecti
agent
endotoxin
skew
immun
system
toward
vigor
system
suppress
respons
allergen
hypothesi
continu
studi
exercis
common
precipit
asthma
symptom
exerciseinduc
bronchospasm
includ
wheez
cough
short
breath
children
chest
pain
discomfort
onset
symptom
typic
min
exercis
begin
min
exercis
complet
sport
commonli
associ
precipit
symptom
asthma
aerob
natur
run
crosscountri
ski
compar
requir
high
ventilatori
rate
weight
lift
dive
symptom
intens
min
usual
resolv
within
min
degre
bronchoconstrict
rare
sever
enough
life
threaten
sever
often
compon
poorli
control
underli
diseas
concomit
allergen
irrit
exposur
exerciseinduc
bronchospasm
confirm
spirometri
show
decreas
exercis
addit
peak
flow
read
perform
exercis
document
decreas
airflow
diagnosi
also
suspect
allevi
symptom
use
prophylact
medic
exercis
phenomenon
discuss
detail
sect
special
group
vocal
cord
dysfunct
particularli
diagnosi
manag
discuss
section
differenti
diagnosi
although
vocal
cord
dysfunct
present
asthma
masquerad
common
asthma
vocal
cord
dysfunct
coexist
mani
patient
diagnosi
vocal
cord
dysfunct
also
airway
hyperrespons
estim
asthma
patient
may
compon
vocal
cord
dysfunct
interest
comorbid
asthma
also
associ
vocal
cord
dysfunct
includ
rhiniti
gerd
rhiniti
gerd
treat
minim
contribut
irrit
vocal
cord
coexist
vocal
cord
dysfunct
consid
patient
known
asthma
becom
difficult
control
particularli
clinic
pattern
featur
sudden
onset
resolut
symptom
minim
respons
increas
asthma
therapi
symptom
local
vocal
cord
person
asthma
sensit
without
asthma
air
pollut
irrit
environment
cigarett
smoke
traffic
emiss
photochem
smog
compon
increas
pollut
level
includ
particul
sulfur
dioxid
nitric
oxid
increas
asthma
symptom
ozon
exposur
proxim
major
roadway
associ
increas
incid
diseas
recent
complex
organ
molecul
diesel
exhaust
particl
associ
worsen
asthma
may
also
act
pollut
allerg
adjuv
airway
inflamm
enhanc
sever
immunemedi
lung
diseas
irrit
pollut
cigarett
smoke
studi
like
import
indoor
pollut
harm
human
health
tobacco
smoke
contain
chemic
substanc
mani
carcinogen
mutagen
irrit
toxic
postnat
exposur
environment
tobacco
smoke
show
causal
link
develop
asthma
childhood
dose
depend
strongest
effect
detect
youngest
children
also
evid
environment
tobacco
smoke
exposur
relat
increas
risk
adultonset
asthma
risk
often
strongli
relat
workplac
environment
tobacco
smoke
exposur
oppos
home
exposur
evid
relationship
although
extens
evid
show
ambient
air
pollut
exacerb
exist
asthma
link
develop
asthma
less
establish
suggest
approxim
occup
asthmagen
exposur
industri
workplac
often
identifi
offend
agent
usual
isol
occup
asthma
prevent
success
identif
reduct
workplac
exposur
enzym
deterg
industri
use
powder
natur
rubber
latex
glove
health
care
industri
import
inquir
exposur
pollut
irrit
home
work
environ
particularli
environment
cigarett
smoke
parent
educ
encourag
smoke
quit
alreadi
smoker
reduc
childhood
exposur
asthmagen
recogn
workplac
issu
respect
exposur
avoid
need
address
addit
studi
link
irrit
pollut
asthma
need
help
determin
effect
way
individu
protect
link
upper
airway
lower
airway
diseas
long
interest
clinician
recent
epidemiolog
immunolog
therapeut
link
establish
among
rhiniti
sinus
asthma
led
concept
unit
airway
diseas
allerg
rhinobronch
exist
unit
airway
first
deduc
epidemiolog
studi
sever
crosssect
studi
shown
associ
rhiniti
asthma
patient
rhiniti
asthma
rhiniti
occur
patient
asthma
longitudin
studi
confirm
link
shown
rhiniti
usual
preced
risk
factor
asthma
even
independ
atop
statu
physiolog
immunolog
standpoint
sever
studi
shown
upper
lower
respiratori
airway
behav
singl
entiti
shown
high
percentag
patient
perenni
allerg
rhiniti
alon
without
clinic
diagnosi
asthma
bronchial
hyperreact
obstruct
spirometr
impair
direct
correl
degre
nonspecif
bronchial
respons
methacholin
challeng
degre
nonspecif
nasal
respons
histamin
challeng
shown
patient
asthma
rhiniti
bronchial
mucos
inflamm
mirror
chang
seen
nose
allergen
challeng
chang
bidirect
wherebi
nasal
challeng
result
nose
bronchial
inflamm
bronchial
challeng
also
result
nose
bronchial
inflamm
mechan
crosstalk
nose
lung
clarifi
complet
hypothes
system
event
mediat
neurohumor
mechan
effect
cytokin
releas
bone
marrow
link
rhiniti
asthma
also
shown
effect
medic
nose
lung
treatment
rhiniti
intranas
corticosteroid
favor
effect
bronchial
symptom
studi
shown
correct
treatment
rhiniti
significantli
reduc
rate
hospit
admiss
emerg
depart
visit
asthma
exacerb
antihistamin
shown
reduc
asthma
symptom
bronchodil
use
patient
allerg
rhiniti
asthma
allergen
immunotherapi
shown
decreas
symptom
asthma
help
prevent
develop
asthma
adult
children
season
perenni
rhiniti
asthma
patient
assess
care
rhiniti
environment
histori
symptom
physic
examin
appropri
treatment
rhiniti
allow
better
manag
asthma
may
also
favor
alter
cours
develop
countri
approxim
adult
asthma
current
smoker
anoth
former
smoker
asthma
patient
smoke
wors
symptom
control
greater
need
rescu
medic
acceler
decreas
lung
function
increas
mortal
rate
year
nearfat
asthma
attack
alter
airway
inflammatori
cell
milieu
decreas
therapeut
respons
corticosteroid
numer
inflammatori
chang
asthma
patient
smoke
compar
asthma
patient
smoke
interest
number
eosinophil
increas
sputum
sampl
asthma
patient
smoke
smoker
proinflammatori
cytokin
increas
includ
antiinflammatori
cytokin
decreas
exhal
nitric
oxid
level
decreas
smoker
mild
asthma
compar
nonsmok
cigarett
smoke
may
decreas
exhal
nitric
oxid
inhibit
induc
nitric
oxid
synthetas
normal
smoker
exhal
nitric
oxid
level
increas
smoke
cessat
current
clear
effect
import
caus
asthma
difficulti
cigarett
smoke
asthma
combin
acceler
lung
function
declin
greater
degre
either
variabl
alon
copenhagen
citi
heart
studi
perform
period
found
averag
annual
declin
asthma
patient
nonsmok
ml
wherea
asthma
patient
smoke
ml
male
year
old
perhap
import
long
term
reduc
effect
corticosteroid
asthma
patient
smoke
studi
rang
week
month
asthma
patient
smoke
signific
increas
morn
peak
expiratori
flow
mean
mean
provoc
concentr
requir
elicit
decreas
methacholin
compar
placebo
wherea
chang
note
asthma
patient
smoke
even
oral
prednisolon
fail
provid
signific
improv
morn
pef
asthma
control
score
asthma
patient
smoke
wherea
paramet
improv
asthma
patient
smoke
best
treatment
smoker
asthma
smoke
cessat
former
smoker
oppos
current
smoker
show
improv
morn
pef
valu
oral
corticosteroid
treatment
smoke
cessat
nonasthma
subject
reduc
respiratori
symptom
frequenc
respiratori
infect
time
rate
declin
lung
function
return
never
smoker
data
avail
direct
studi
asthma
patient
smoke
quit
nicotin
replac
therapi
medic
bupropion
set
structur
smoke
cessat
program
like
effect
smoke
cessat
smoker
asthma
unabl
stop
may
requir
altern
treatment
treatment
addit
corticosteroid
cigarett
smoke
induc
cyp
famili
cytochrom
enzym
increas
clearanc
theophyllin
almost
twofold
decreas
halflif
smoker
compar
nonsmok
littl
inform
avail
effect
antiasthma
drug
leukotrien
antagonist
theoret
leukotrien
antagonist
may
benefit
asthma
patient
smoke
cigarett
smoke
induc
higher
level
urinari
leukotrien
medic
potenti
exacerb
asthma
common
medic
implic
exacerb
asthma
blocker
aspirin
nsaid
use
treatment
numer
diseas
state
includ
hypertens
congest
heart
failur
coronari
arteri
diseas
glaucoma
migrain
headach
divid
multipl
group
practic
classif
select
nonselect
select
select
cardioselect
preferenti
block
heart
common
select
includ
atenolol
tenormin
metoprolol
toprol
betaxolol
kerlon
bisoprolol
zebeta
higher
dose
howev
blockad
also
begin
occur
becom
pronounc
dosag
increas
nonselect
block
receptor
heart
well
receptor
bronchial
smooth
muscl
cell
commonli
use
nonselect
includ
propranolol
inder
sotalol
betapac
timolol
blocadren
nadolol
corgard
timolol
betaxolol
betopt
topic
eye
drop
use
treat
glaucoma
even
though
use
topic
report
caus
sever
exacerb
asthma
patient
often
know
name
eye
drop
use
usual
yellow
blue
cap
bottl
gener
nonselect
antagonist
like
induc
bronchospasm
patient
known
asthma
select
howev
sever
exacerb
asthma
report
group
exacerb
occur
patient
mild
moder
sever
asthma
actual
incid
sever
asthma
exacerb
use
cardioselect
nonselect
unknown
certainli
asthma
patient
abl
toler
use
cardioselect
without
difficulti
accord
recent
systemat
review
singl
dose
cardioselect
produc
reduct
wherea
treatment
day
produc
chang
determin
use
treat
asthma
patient
benefittorisk
ratio
requir
review
strictli
migrain
prophylaxi
hypertens
glaucoma
medic
option
like
consid
asthma
patient
patient
sever
angina
coronari
arteri
diseas
congest
heart
failur
shown
decreas
morbid
mortal
cardioselect
consid
particularli
patient
mild
wellcontrol
asthma
howev
test
clinic
pattern
predict
asthma
flare
use
cardioselect
use
patient
counsel
possibl
asthma
exacerb
appropri
measur
institut
manag
possibl
exacerb
nonselect
avoid
aspirin
nsaid
induc
rhinorrhea
bronchospasm
subset
patient
underli
rhinosinus
nasal
polyp
asthma
variou
term
use
describ
phenomenon
includ
aspirin
intoler
aspirin
sensit
aspirininduc
asthma
aspirin
idiosyncrasi
current
call
aspirinexacerb
respiratori
diseas
aerd
aspirin
nsaid
inhibit
caus
reaction
reaction
dose
depend
small
dose
may
induc
reaction
larg
dose
may
although
aspirin
nsaid
exposur
trigger
respiratori
reaction
sometim
sever
underli
asthma
rhinosinus
continu
absenc
exposur
aspirin
nsaid
except
sensit
aspirin
nsaid
patient
differenti
patient
asthma
sinu
diseas
preval
aspirin
nsaid
sensit
among
asthma
patient
associ
rhinosinus
nasal
polyp
approxim
asthma
patient
without
nasal
polyposi
aspirin
nsaid
sensit
approxim
skin
test
vitro
test
identifi
patient
reaction
ige
mediat
reaction
mediat
inhibit
result
decreas
protect
prostaglandin
increas
product
inflammatori
leukotrien
prostaglandin
nsaid
inhibit
crossreact
aspirin
induc
respiratori
reaction
includ
commonli
use
nsaid
indomethacin
ibuprofen
naproxen
weak
inhibitor
acetaminophen
salsal
produc
respiratori
reaction
patient
aerd
typic
occur
larg
dose
small
proport
patient
select
inhibitor
celecoxib
rofecoxib
appear
crossreact
aspirin
appear
safe
patient
aerd
patient
aerd
aspirin
nsaid
therapi
critic
patient
coronari
arteri
diseas
need
aspirin
prophylaxi
patient
sever
arthriti
unrespons
treatment
patient
aerd
intract
nasal
polyp
format
rhinosinus
aspirin
given
supervis
grade
desensit
protocol
protocol
outlin
chapter
rhinosinus
pathogenesi
aspirin
desensit
larg
unknown
result
aspirin
nsaid
toler
continu
daili
time
downregul
leukotrien
product
occup
asthma
often
overlook
caus
asthma
review
end
chapter
section
special
group
obstruct
sleep
apnea
character
intermitt
partial
total
airway
occlus
sleep
associ
seriou
health
consequ
includ
insulin
resist
hypertens
cardiovascular
diseas
worsen
asthma
control
estim
adult
mild
obstruct
sleep
apnea
nearli
moder
sever
major
patient
nighttim
asthma
symptom
sever
asthma
obstruct
sleep
apnea
treatment
continu
posit
airway
pressur
significantli
improv
nighttim
symptom
control
littl
chang
baselin
spirometri
true
incid
gerd
asthma
caus
factor
asthma
sever
fulli
establish
estim
asthma
patient
gerd
epidemiolog
evid
establish
associ
gerd
asthma
evid
support
caus
role
propos
mechan
gerd
may
affect
asthma
includ
microaspir
gastric
reflux
vagal
mediat
esophagobronchi
reflex
mechan
subsequ
bronchospasm
although
uniqu
clinic
identifi
establish
whether
gerd
contribut
asthma
consid
difficulttocontrol
asthma
nonallerg
asthma
asthma
moder
sever
gerd
nocturn
asthma
clinic
suspicion
critic
compon
diagnosi
gerdinduc
asthma
patient
histori
suggest
condit
empir
trial
highdos
proton
pump
inhibitor
month
reason
strategi
appreci
chang
spirometri
short
term
typic
seen
esophag
ph
monitor
perform
asthma
patient
gerd
symptom
respond
empir
trial
proton
pump
inhibitor
patient
asymptomat
gerd
silent
gerd
may
role
silent
gerd
may
present
onethird
asthma
patient
surgic
therapi
gerdtrigg
asthma
may
hold
promis
thu
far
data
consist
mainli
uncontrol
studi
addit
larg
random
studi
subgroup
patient
asthma
treat
proton
pump
inhibitor
surgic
intervent
help
clarifi
role
gerd
treatment
asthma
asthma
chronic
diseas
educ
serv
foundat
built
upon
obtain
diseas
control
key
point
emphas
asthma
educ
includ
understand
basic
asthma
rational
use
differ
medic
import
complianc
medic
correct
use
variou
inhal
peak
flow
meter
environment
modif
trigger
asthma
recogn
respond
asthma
symptom
know
call
physician
seek
emerg
depart
care
seem
selfevid
howev
address
patient
repeatedli
chronic
diseas
complianc
becom
poor
result
poor
diseas
control
asthma
educ
onetim
experi
effect
asthma
educ
need
ongo
experi
build
time
requir
time
dedic
health
care
team
commun
patient
need
establish
treatment
goal
result
patient
live
normal
lifestyl
minim
symptom
reduc
risk
asthma
exacerb
inhal
medic
current
use
asthma
avail
mdi
mdi
technolog
use
primarili
chlorofluorocarbon
propel
chlorofluorocarbon
constitut
approxim
formul
releas
mdi
howev
found
deplet
stratospher
ozon
follow
adopt
montreal
protocol
intern
agreement
place
ban
chlorofluorocarbon
altern
includ
mdi
propel
hydrofluoroalkan
dpi
us
food
drug
administr
fda
approv
process
new
inhal
requir
replac
product
demonstr
compar
correspond
chlorofluorocarboncontain
inhal
clinician
patient
anticip
similar
effect
safeti
new
product
current
fluticason
levalbuterol
albuterol
avail
hydrofluoroalkan
formul
spacer
valv
hold
chamber
accessori
devic
reduc
oropharyng
deposit
drug
enhanc
lung
deliveri
minim
import
coordin
spacer
devic
openend
tube
allow
mdi
plume
slow
propel
evapor
inhal
valv
hold
chamber
incorpor
oneway
valv
trap
plume
allow
aerosol
deliv
chamber
inspir
valv
hold
chamber
incorpor
mask
patient
unabl
use
mouthpiec
age
poor
coordin
impair
mental
statu
accessori
devic
wash
dishwash
deterg
allow
air
dri
remov
residu
medic
elimin
static
charg
dpi
function
draw
air
dose
powder
medic
requir
inspir
rel
high
inspiratori
flow
rate
larger
carrier
particl
impact
oropharynx
give
patient
sensat
inhal
dose
howev
impact
less
mdi
patient
may
feel
receiv
medic
dpi
breath
actuat
thu
coordin
manual
inhal
actuat
inspir
requir
howev
magnitud
durat
patient
inspiratori
effort
influenc
aerosol
gener
dpi
devic
use
cautious
young
elderli
neuromuscular
weak
dpi
requir
manual
manipul
load
dose
may
difficult
patient
limit
dexter
dpi
requir
use
space
devic
nebul
requir
pressur
ga
suppli
allow
liquid
atom
medic
sever
factor
contribut
effici
nebul
includ
respir
dose
nebul
time
dead
volum
patient
interfac
respir
dose
function
total
output
nebul
size
particl
produc
droplet
size
airway
deposit
parenchym
deposit
nebul
time
import
determin
patient
complianc
outpati
set
function
volum
drug
deliv
flow
rate
drive
ga
treatment
complet
nebul
begin
sputter
although
nebul
typic
use
intermitt
continu
nebul
administ
emerg
depart
hospit
treatment
acut
asthma
volum
medic
trap
insid
nebul
refer
dead
volum
devic
volum
typic
rang
ml
increas
fill
volum
help
decreas
proport
dose
lost
dead
volum
maneuv
increas
nebul
time
consid
factor
nebul
fill
volum
ml
gener
recommend
nebul
solut
within
nebul
becom
increasingli
concentr
water
evapor
solut
therefor
per
breath
medic
deliv
late
cours
treatment
nebul
aerosol
administ
mouthpiec
face
mask
signific
facial
eye
deposit
occur
face
mask
use
mouth
piec
usual
favor
gener
home
use
mdi
dpi
recommend
nebul
reserv
sever
acut
exacerb
patient
unabl
toler
mdi
dpi
nebul
option
corticosteroid
potent
effect
longterm
control
medic
asthma
antiinflammatori
properti
includ
suppress
airway
eosinophil
recruit
suppress
cytokin
product
suppress
inflammatori
mediat
releas
clinic
effect
includ
reduct
sever
symptom
improv
pefr
spirometri
diminish
airway
hyperrespons
prevent
exacerb
possibl
prevent
airway
remodel
inhal
corticosteroid
consid
firstlin
treatment
patient
mild
moder
sever
persist
asthma
singl
agent
inhal
corticosteroid
effect
theophyllin
salmeterol
nedocromil
leukotrien
modifi
manag
asthma
choic
specif
inhal
corticosteroid
depend
potenc
corticosteroid
requir
deliveri
devic
signific
differ
potenc
among
variou
inhal
corticosteroid
tabl
realiz
differ
import
initi
adjust
therapi
exampl
patient
moderatetosever
persist
asthma
potent
corticosteroid
budesonid
fluticason
would
use
instead
triamcinolon
beclomethason
effort
minim
puff
contrast
patient
mild
persist
asthma
lower
potenc
corticosteroid
could
prescrib
fluticason
triamcinolon
beclomethason
principl
patient
receiv
lowest
effect
dose
requir
achiev
good
asthma
control
basi
evalu
symptom
supplement
bronchodil
use
exacerb
peak
flow
spirometri
possibl
sputum
eosinophil
exhal
nitric
oxid
dose
inhal
corticosteroid
adjust
lowest
effect
dose
use
safeti
inhal
corticosteroid
studi
extens
system
effect
identifi
particularli
high
dose
clinic
signific
unclear
may
interindividu
variat
effect
gener
potenti
advers
effect
must
weigh
risk
uncontrol
asthma
date
evid
support
use
inhal
corticosteroid
common
side
effect
inhal
corticosteroid
local
advers
effect
oral
candidiasi
thrush
dysphonia
oral
candidiasi
frequent
adult
children
typic
seen
high
dose
inhal
corticosteroid
use
significantli
decreas
risk
oral
candidiasi
develop
spacer
devic
use
mdi
formul
method
inhal
mouth
rins
inhal
use
dysphonia
seen
primarili
high
dose
inhal
corticosteroid
prevent
treat
rins
mouth
inhal
use
spacer
devic
reduc
dosag
rest
voic
studi
system
side
effect
inhal
corticosteroid
includ
linear
growth
bone
metabol
osteoporosi
hypothalamicpituitari
axi
function
cataract
effect
inhal
corticosteroid
growth
children
difficult
studi
multipl
confound
factor
growth
includ
concomit
use
system
corticosteroid
concomit
atopi
asthma
studi
children
asthma
treat
inhal
corticosteroid
identifi
growth
delay
other
shown
differ
even
growth
delay
appear
expect
height
still
attain
decreas
cm
lowtomedium
dose
inhal
corticosteroid
appear
seriou
advers
effect
bone
miner
densiti
children
small
dosedepend
decreas
bone
miner
densiti
may
found
adult
clinic
signific
clear
children
lowtomedium
dose
inhal
corticosteroid
therapi
signific
effect
incid
subcapsular
cataract
glaucoma
adult
high
lifetim
exposur
inhal
corticosteroid
may
increas
preval
cataract
associ
glaucoma
longterm
highdos
inhal
corticosteroid
may
seen
famili
histori
glaucoma
leukotrien
inflammatori
mediat
releas
mast
cell
eosinophil
basophil
product
arachadon
acid
metabol
leukotrien
caus
contract
airway
smooth
muscl
increas
vascular
permeabl
increas
mucu
secret
recruit
inflammatori
cell
airway
leukotrienemodifi
agent
divid
two
group
inhibitor
zileuton
leukotrienereceptor
antagonist
zafirlukast
montelukast
zileuton
inhibit
format
leukotrien
zafirlukast
montelukast
inhibit
bind
cysteinyl
leukotrien
leukotrien
receptor
leukotrien
modifi
indic
monotherapi
treatment
mild
persist
asthma
consid
patient
prefer
oral
agent
unabl
unwil
use
inhal
corticosteroid
compar
overal
effect
leukotrien
modifi
inhal
corticosteroid
outcom
measur
significantli
favor
inhal
corticosteroid
leukotrien
modifi
use
combin
inhal
corticosteroid
moder
sever
persist
asthma
leukotrien
modifi
help
reduc
symptom
allerg
rhiniti
may
consider
patient
coexist
asthma
allerg
rhiniti
zileuton
may
increas
liver
transaminas
followup
liver
transaminas
test
recommend
monthli
month
everi
month
rest
first
year
period
thereaft
longterm
therapi
specif
recommend
made
monitor
liver
transaminas
conjunct
zafirlukast
montelukast
therapi
leukotrien
modifi
link
case
vascul
observ
suggest
case
primari
eosinophil
disord
unmask
system
corticosteroid
taper
leukotrienemodifi
therapi
howev
eosinophil
disord
associ
leukotrien
modifi
treatment
even
absenc
previou
corticosteroid
therapi
associ
true
appear
rare
zileuton
approv
children
older
year
adult
dosag
mg
four
time
daili
montelukast
mg
daili
administ
granul
chewabl
tablet
form
children
month
year
old
dosag
age
year
mg
daili
year
older
mg
daili
zafirlukast
dosag
mg
twice
daili
age
year
mg
twice
daili
year
older
concomit
use
warfarin
result
higher
warfarin
level
subsequ
higher
prothrombin
time
level
thu
close
monitor
adjust
advis
nedocromil
cromolyn
mild
antiinflammatori
agent
inhibit
releas
mast
cell
mediat
inhibit
earli
late
phase
respons
allergen
challeng
bronchoprotect
exercis
secondlin
agent
may
use
treat
mild
persist
asthma
prophylaxi
exerciseinduc
asthma
allergeninduc
asthma
effect
nedocromil
cromolyn
similar
leukotrien
antagonist
theophyllin
less
effect
inhal
corticosteroid
cromolyn
avail
mdi
dpi
solut
nebul
nedocromil
avail
mdi
usual
dose
two
puff
four
time
daili
although
nedocromil
may
given
twice
daili
signific
advers
effect
patient
find
tast
nedocromil
unpleas
nedocromil
cromolyn
recommend
moder
sever
persist
asthma
theophyllin
function
nonselect
inhibitor
cyclic
adenosin
monophosph
phosphodiesteras
airway
smooth
muscl
result
bronchodilat
theophyllin
inhibit
activ
inflammatori
cell
vitro
howev
clinic
import
antiinflammatori
effect
appear
small
theophyllin
second
thirdlin
agent
daili
treatment
persist
asthma
sustainedreleas
theophyllin
effect
nocturn
asthma
moder
sever
persist
asthma
theophyllin
given
combin
inhal
corticosteroid
theophyllin
use
limit
side
effect
profil
advers
effect
includ
nausea
headach
insomnia
diarrhea
irrit
tremor
recommend
therapeut
rang
lower
dose
provid
serum
level
usual
toler
better
higher
dose
theophyllin
metabol
cytochrom
signific
drug
interact
medicin
decreas
clearanc
theophyllin
thu
increas
theophyllin
level
includ
macrolid
antibiot
fluoroquinolon
antibiot
propranolol
diltiazem
verapamil
disulfiram
oral
contracept
medic
increas
theophyllin
clearanc
decreas
theophyllin
level
includ
phenytoin
phenobarbit
cimetidin
patient
treat
sever
year
theophyllin
care
must
taken
discontinu
medic
abrupt
withdraw
theophyllin
caus
exacerab
asthma
theophyllin
treatment
discontinu
recommend
theophyllin
taper
slowli
patient
awar
possibl
asthma
exacerb
novemb
fda
issu
advisori
use
longact
asthma
request
manufactur
includ
warn
label
agent
may
worsen
asthma
exacerb
increas
risk
death
base
primarili
salmeterol
multicent
asthma
research
trial
smart
random
doubleblind
placebocontrol
observ
studi
small
statist
signific
increas
respiratoryrel
asthmarel
death
combin
asthmarel
death
lifethreaten
experi
total
popul
receiv
salmeterol
risk
appear
greater
african
american
caucasian
effect
concomit
inhal
corticosteroid
use
abl
interpret
studi
design
lack
control
multipl
variabl
interpret
result
studi
subsequ
fda
warn
engend
signific
controversi
expert
favor
warn
other
think
overreach
gener
agreement
mildtomoder
persist
asthma
inhal
corticosteroid
administ
suffici
amount
control
symptom
wherea
patient
sever
diseas
still
requir
daili
administr
albuterol
addit
adequ
dose
inhal
corticosteroid
longact
may
ad
reliev
symptom
longact
extend
hydrophob
side
chain
interact
lipid
bilay
cell
membran
lead
prolong
durat
action
bronchodilat
begin
approxim
min
inhal
salmeterol
peak
respons
reach
sever
hour
bronchodilat
begin
min
inhal
formoterol
peak
bronchodilat
h
durat
action
salmeterol
formoterol
approxim
h
salmeterol
avail
mdi
dpi
form
formoterol
avail
dpi
form
primari
advers
effect
longact
similar
shortact
name
tremor
increas
heart
rate
continu
use
salmeterol
decreas
bronchoprotect
effect
salmeterol
exercis
bronchial
challeng
inhal
longact
use
rescu
quick
relief
asthma
symptom
control
agent
longact
use
singl
agent
lack
antiinflammatori
effect
longact
effect
adjunct
inhal
corticosteroid
treatment
moderatetosever
persist
asthma
particularli
effect
treatment
nocturn
asthma
recommend
dose
inhal
longact
two
puff
twice
daili
salmeterol
mdi
one
puff
twice
daili
salmeterol
formoterol
dpi
inhal
shortact
indic
immedi
asneed
control
asthma
symptom
often
describ
rescu
therapi
also
shortact
use
prophylaxi
exerciseinduc
asthma
asthma
provok
allerg
trigger
shortact
select
act
bronchodil
relax
bronchial
smooth
muscl
receptor
also
found
heart
caus
sympathomimet
side
effect
tachycardia
palpit
tremor
shortact
given
nebul
mdi
oral
form
primari
use
albuterol
pirbuterol
levalbuterol
levalbuterol
risom
racem
albuterol
contain
risom
less
albuterol
use
achiev
amount
bronchodil
shortact
onset
bronchodil
occur
within
minut
peak
min
durat
action
h
overus
link
increas
asthma
morbid
mortal
author
believ
caus
morbid
mortal
rather
overus
marker
sever
undertr
asthma
patient
use
canist
shortact
monthli
entir
treatment
program
review
amount
repres
warn
overal
poorli
control
asthma
shortact
taken
asneed
basi
regular
daili
treatment
shortact
advantag
system
oral
corticosteroid
indic
treatment
acut
asthma
sever
persist
asthma
patient
whose
asthma
well
control
highdos
inhal
corticosteroid
longact
mani
oral
corticosteroid
product
avail
prednison
best
studi
least
expens
oral
corticosteroid
commonli
use
treat
asthma
advers
effect
prolong
use
oral
corticosteroid
includ
hyperglycemia
growth
suppress
osteoporosi
posterior
subcapsular
cataract
fat
redistribut
skin
thin
bruis
mood
chang
suppress
hypothalamicpituitari
axi
hospit
patient
without
risk
impend
ventilatori
failur
oral
prednison
appear
effect
intraven
corticosteroid
prednison
mg
per
day
mg
daili
children
may
given
divid
dose
patient
mild
asthma
typic
well
control
exacerb
asthma
gener
resolv
cours
prednison
patient
requir
longterm
prednison
treatment
dose
titrat
lowest
effect
dose
prednison
administ
daili
altern
day
alternateday
regimen
may
help
reduc
system
advers
effect
control
asthma
assess
period
evalu
symptom
supplement
bronchodil
use
exacerb
peak
flow
spirometri
adjust
dose
lowest
effect
dose
patient
receiv
continu
dose
blood
pressur
height
weight
glucos
bone
densiti
cataract
assess
period
adult
may
benefit
prevent
approach
calcium
mg
per
day
vitamin
age
year
iu
per
day
year
iu
per
day
supplement
anticholinerg
medic
carri
approv
indic
use
asthma
although
may
use
altern
peopl
intoler
side
effect
anticholinerg
medic
firstlin
bronchodil
patient
copd
patient
combin
asthma
copd
like
benefit
medic
anticholinerg
agent
block
muscarin
receptor
regul
airway
tone
mucu
product
result
bronchodil
anticholinerg
agent
avail
shortact
form
ipratropium
bromid
atrov
longact
form
tiotropium
bromid
spiriva
ipratropium
given
nebul
form
mdi
bronchodil
peak
approxim
h
inhal
last
h
ipratropium
also
avail
combin
form
albuterol
combiv
avail
mdi
nebul
form
tiotropium
avail
dpi
handihal
devic
dose
one
inhal
daili
bronchodil
occur
period
main
side
effect
anticholinerg
agent
dri
mouth
occasion
cough
may
potenti
worsen
symptom
associ
narrowangl
glaucoma
prostat
hyperplasia
bladder
neck
obstruct
prescrib
caution
patient
condit
omalizumab
human
antiig
monoclon
antibodi
drug
bind
fc
portion
ige
prevent
ige
bind
ige
receptor
mast
cell
omalizumab
decreas
serum
level
ige
least
disrupt
type
igemedi
hypersensit
reaction
therefor
omalizumab
use
treatment
allerg
asthma
current
fdaapprov
indic
omalizumab
moderatetosever
persist
allerg
asthma
medic
given
subcutan
either
everi
week
everi
week
depend
dosag
requir
dose
base
patient
weight
total
ige
level
allergen
test
requir
establish
allerg
sensit
perform
allergen
skin
prick
test
vitro
studi
ige
bind
pertin
aeroallergen
clinic
studi
omalizumab
children
older
year
adult
result
improv
symptom
fewer
diseas
exacerb
decreas
use
asthma
medic
corticosteroid
howev
minim
chang
measur
airflow
airway
hyperreact
shown
omalizumab
publish
clinic
studi
compar
safeti
effect
omalizumab
corticosteroid
current
omalizumab
appear
effect
antiinflammatori
agent
primarili
sever
allerg
asthma
precis
role
manag
allerg
asthma
defin
fulli
box
warn
ad
product
label
omalizumab
xolair
address
risk
anaphylaxi
estim
least
postmarket
studi
risk
anaphylaxi
recommend
omalizumab
administ
medic
supervis
provid
abl
treat
anaphylaxi
anaphylaxi
occur
dose
drug
onset
delay
administr
allergen
immunotherapi
consist
inject
allergen
extract
patient
allerg
induc
immunolog
toler
asthma
airborn
allergen
anim
dander
dust
mite
mold
tree
grass
weed
pollen
inject
neutral
allerg
trigger
asthma
sensit
patient
appear
multipl
mechan
allergen
immunotherapi
abl
induc
toler
includ
increas
igg
block
antibodi
gener
suppressor
tcell
deviat
cytokin
releas
profil
product
tcell
toler
sever
studi
document
improv
asthma
symptom
patient
receiv
immunotherapi
howev
control
studi
consist
posit
metaanalysi
found
odd
ratio
symptomat
improv
immunotherapi
ci
revis
metaanalysi
author
incorpor
new
studi
show
highli
signific
improv
symptom
nonspecif
bronchial
hyperreact
risk
symptom
deterior
immunotherapi
group
patient
persist
season
allerg
nasal
symptom
well
asthma
appear
benefit
nation
asthma
educ
prevent
program
expert
panel
report
recommend
allergen
immunotherapi
consid
clear
evid
relat
symptom
exposur
unavoid
allergen
symptom
occur
major
portion
entir
year
symptom
difficult
control
pharmacolog
manag
evalu
airborn
allergen
requir
establish
allerg
sensit
perform
allergen
skin
prick
test
vitro
studi
ige
bind
unit
state
standard
practic
allergen
immunotherapi
start
dilut
mainten
concentr
variou
protocol
use
dose
typic
increas
interv
everi
day
buildup
phase
mainten
dose
achiev
mainten
dose
achiev
inject
given
everi
week
length
treatment
immunotherapi
well
defin
although
year
consid
normal
cours
treatment
initi
respons
treatment
requir
approxim
month
among
patient
improv
immunotherapi
major
continu
improv
cours
treatment
end
approxim
return
symptom
soon
treatment
method
predict
patient
prolong
improv
recurr
allergi
main
risk
allergen
immunotherapi
develop
sever
allerg
reaction
asthma
exacerb
immunotherapi
inject
sever
reaction
immunotherapi
rare
fatal
occur
fewer
one
per
million
inject
reduc
risk
reaction
patient
select
appropri
educ
warn
symptom
patient
brittl
unstabl
asthma
baselin
increas
risk
reaction
exclud
immunotherapi
asthma
patient
peak
flow
rate
measur
inject
inject
postpon
clinic
peak
flow
evid
exacerb
patient
observ
min
immunotherapi
inject
inject
given
personnel
train
equip
use
epinephrin
parent
glucocorticoid
intraven
fluid
intub
equip
nebul
physic
find
patient
exacerb
alway
correl
well
degre
airflow
obstruct
although
diffus
expiratori
wheez
common
find
patient
sever
impair
may
decreas
breath
sound
limit
auscultatori
wheez
treatment
initi
wheez
may
becom
manifest
symptom
acut
asthma
attack
includ
sensat
air
hunger
chest
tight
cough
fatigu
inabl
lie
flat
sign
acut
exacerb
includ
use
accessori
muscl
respir
wheez
diaphoresi
inabl
complet
sentenc
alter
mental
statu
omin
sign
necessit
immedi
emerg
care
hospit
physic
examin
includ
close
monitor
vital
sign
blood
pressur
puls
respiratori
rate
detail
examin
nose
throat
chest
patient
sever
exacerb
usual
increas
puls
respiratori
rate
abnorm
pulsu
paradoxu
pulsu
paradoxu
differ
systol
blood
pressur
taken
inspir
expir
pulsu
paradoxu
mmhg
occur
moder
obstruct
one
mmhg
sever
obstruct
peak
expiratori
flow
read
spirometri
quantifi
obstruct
spirometri
may
difficult
perform
set
sever
exacerb
peak
flow
read
predict
person
best
consist
sever
exacerb
consist
moder
exacerb
mild
exacerb
treatment
base
clinic
find
subject
object
peak
flow
read
previou
underli
diseas
treatment
approach
differ
patient
mild
asthma
season
polleninduc
exacerb
one
moderatetosever
persist
asthma
respiratori
infect
alreadi
use
nebul
albuterol
home
latter
patient
usual
requir
aggress
manag
corticosteroid
form
cornerston
initi
treatment
oxygen
also
recommend
except
mild
acut
exacerb
overview
manag
acut
asthma
given
fig
approxim
patient
achiev
maxim
bronchodil
one
unit
dose
mg
albuterol
nebul
ml
normal
salin
therapi
repeat
everi
min
patient
condit
stabl
decis
made
hospit
patient
approxim
patient
achiev
respons
three
dose
mg
inhal
albuterol
therefor
patient
clinic
statu
dose
albuterol
often
better
indic
rather
initi
present
whether
inpati
care
requir
levalbuterol
thirdgener
consist
renantiom
albuterol
respons
bronchodilatori
effect
approv
age
year
older
usual
start
dose
mg
unit
dosag
thu
fewer
system
side
effect
albuterol
mg
highest
levalbuterol
dose
recommend
mg
solut
approv
use
everi
h
like
given
repeatedli
like
albuterol
conflict
studi
result
clearcut
benefit
levalbuterol
compar
albuterol
corticosteroid
help
treatment
acut
asthma
even
though
rapid
onset
action
immedi
revers
process
antiinflammatori
properti
help
prevent
exacerb
escal
shorten
time
exacerb
addit
treatment
mani
patient
mild
exacerb
asthma
treat
success
higherthanrecommend
dose
inhal
corticosteroid
exampl
dose
inhal
fluticason
may
increas
two
puff
four
time
daili
instead
usual
top
dose
two
puff
twice
daili
period
inhal
corticosteroid
use
similarli
doubl
tripl
highest
recommend
dose
howev
strategi
less
like
work
patient
moder
sever
exacerb
overus
sever
upper
respiratori
infect
exacerb
asthma
short
cours
prednison
system
corticosteroid
usual
effect
establish
control
exacerb
asthma
medic
effect
given
earli
exacerb
children
common
steroid
burst
mg
daili
day
adult
prednison
mg
daili
day
patient
consider
improv
day
taper
dose
system
corticosteroid
requir
short
cours
week
system
corticosteroid
treatment
longer
day
advis
taper
medic
help
lessen
side
effect
steroid
withdraw
includ
fatigu
depress
myalgia
arthralgia
essenti
exacerb
asthma
corticosteroid
treatment
implement
increas
continu
day
exacerb
ensur
stabil
exampl
mild
moder
exacerb
improv
consider
two
treatment
nebul
albuterol
often
follow
relaps
corticosteroid
either
inhal
system
also
start
increas
corticosteroid
also
given
intraven
intramuscularli
evid
intraven
intramuscular
corticosteroid
faster
onset
action
oral
corticosteroid
hospit
patient
common
approach
administ
intraven
methylprednisolon
mg
three
time
daili
first
h
dosag
adjust
depend
patient
respons
intraven
corticosteroid
advis
set
sever
dyspnea
nausea
vomit
associ
asthma
exacerb
asthma
patient
present
emerg
depart
earli
use
corticosteroid
result
fewer
hospit
statu
asthmaticu
defin
sever
exacerb
asthma
respond
aggress
bronchodil
therapi
patient
statu
asthmaticu
verg
acut
respiratori
failur
risk
intub
mechan
ventilatori
support
common
sign
tachypnea
tachycardia
use
accessori
muscl
respir
despit
aggress
bronchodil
treatment
statu
asthmaticu
treat
oxygen
intraven
corticosteroid
nebul
frequent
everi
h
continu
basi
patient
wean
condit
improv
treatment
includ
close
observ
intens
care
unit
especi
first
h
monitor
progress
respiratori
failur
correct
acidbas
imbal
help
therapi
respiratori
failur
occur
despit
intens
medic
manag
artifici
mechan
ventil
indic
previous
guidelin
asthma
manag
outlin
treatment
recommend
basi
assess
asthma
sever
guidelin
provid
algorithm
increas
dosag
medic
ad
treatment
practic
applic
recommend
challeng
variabl
natur
asthma
minim
symptom
patient
poor
complianc
medic
homebas
measur
patient
alreadi
take
control
medic
asthma
sever
assess
respons
lack
treatment
asthma
sever
therapeut
respons
howev
alway
strictli
correl
help
circumv
issu
naepp
guidelin
recommend
evalu
asthma
sever
guid
choic
appropri
medic
therapeut
intervent
patient
newli
diagnos
untreat
asthma
therapi
initi
evalu
patient
asthma
shift
assess
level
asthma
control
guid
decis
adjust
therapi
asthma
control
assess
sever
paramet
includ
symptom
nighttim
awaken
interfer
normal
activ
use
spirometri
valid
questionnair
exacerb
asthma
control
goal
reduc
antiinflammatori
medic
lowest
effect
dose
current
level
durat
control
requir
downward
titrat
undertaken
strategi
adjust
accomplish
known
gener
rule
consid
step
treatment
asthma
well
control
least
month
biolog
marker
inflamm
eosinophil
sputum
count
exhal
nitric
oxid
level
may
help
process
refin
applic
clinic
set
classif
asthma
sever
take
account
impair
risk
provid
guid
initi
asthma
therapi
initi
therapi
base
sever
outlin
tabl
age
year
tabl
age
year
therapi
select
patient
respons
treatment
guid
decis
adjust
therapi
base
control
impair
risk
factor
although
asthma
patient
requir
individu
care
gener
rule
help
guid
therapi
decis
children
persist
asthma
whether
mild
moder
sever
daili
longterm
control
medic
indic
inhal
corticosteroid
prefer
therapi
initi
longterm
control
therapi
children
mild
asthma
recognit
appropri
longterm
control
therapi
difficult
children
often
asymptomat
episod
indic
use
consider
longterm
control
medic
age
group
also
includ
follow
three
episod
wheez
last
longer
day
within
past
year
risk
factor
develop
asthma
includ
atop
dermat
sensit
aeroallergen
parent
histori
asthma
two
follow
food
allergi
blood
eosinophilia
wheez
absenc
viral
respiratori
infectionrequir
symptomat
treatment
day
weekli
weeksrequir
system
corticosteroid
sever
exacerb
asthma
two
time
within
last
month
situat
treatment
daili
lowdos
inhal
corticosteroid
help
reduc
exacerb
decreas
symptom
appear
alter
futur
cours
asthma
sever
anoth
option
consid
use
daili
control
therapi
period
higher
risk
fall
winter
month
incid
viral
upper
respiratori
tract
infect
higher
approach
evalu
systemat
howev
theoret
help
reduc
symptom
exacerb
patient
mild
asthma
whose
symptom
confin
time
altern
antiinflammatori
longterm
control
option
includ
leukotrien
receptor
antagonist
cromolyn
less
potent
inhal
corticosteroid
consider
initi
treatment
addit
treatment
effect
includ
mode
deliveri
medic
histori
previou
respons
therapi
anticip
complianc
treatment
regimen
follow
fdaapprov
age
indic
control
medic
inhal
corticosteroidsbudesonid
nebul
solut
children
year
fluticason
dpi
children
year
leukotrien
antagonistmontelukast
children
year
chromonescromolyn
nebul
solut
children
year
initi
therapi
pediatr
asthma
classif
asthma
base
impair
risk
provid
guid
initi
therapi
adult
tabl
adult
spirometri
help
clarifi
current
impair
inhal
corticosteroid
prefer
treatment
persist
asthma
requir
longterm
control
medic
altern
includ
cromolyn
leukotrien
receptor
antagonist
sustainedreleas
theophyllin
effect
altern
less
inhal
corticosteroid
aim
asthma
therapi
maintain
longterm
control
asthma
least
amount
medic
achiev
stepwis
approach
therapi
implement
number
medic
amount
medic
increas
necessari
decreas
possibl
maintain
control
emphasi
control
new
key
concept
naepp
report
overview
critic
compon
control
recommend
action
maintain
control
shown
tabl
respect
age
group
year
key
issu
stepwis
approach
includ
add
specif
therapi
tailor
need
circumst
individu
patient
shortact
inhal
taken
need
primari
treatment
intermitt
asthma
requir
quickrelief
treatment
twice
weekli
therapi
increas
persist
asthma
regimen
patient
persist
asthma
receiv
daili
longterm
control
medic
antiinflammatori
effect
overal
inhal
corticosteroid
effect
singl
agent
addit
quickrelief
medic
made
avail
patient
persist
asthma
asthma
control
lowdos
inhal
corticosteroid
despit
excel
complianc
inhal
techniqu
lack
trigger
coexist
condit
therapeut
option
includ
increas
inhal
corticosteroid
dose
mediumdos
rang
ad
longact
low
dose
inhal
corticosteroid
consid
essenti
equal
option
base
risk
benefit
altern
option
includ
ad
leukotrien
antagonist
theophyllin
lowdos
inhal
corticosteroid
next
step
treatment
combin
mediumdos
inhal
corticosteroid
longact
altern
includ
leukotrien
antagonist
theophyllin
addit
mediumdos
inhal
corticosteroid
control
requir
highdos
inhal
corticosteroid
longact
recommend
longterm
studi
assess
efficaci
ad
leukotrien
antagonist
regimen
omalizumab
could
consid
junctur
patient
igemedi
asthma
sensit
pertin
perenni
allergen
allergen
immunotherapi
consid
patient
persist
asthma
relationship
symptom
exposur
allergen
patient
sensit
asthma
highli
variabl
time
treatment
adjust
accordingli
reassess
critic
determin
asthma
control
key
area
monitor
includ
follow
impairmentsymptomsnighttim
awakeningsinterfer
normal
activityshortact
usespirometri
peak
flowvalid
questionnair
riskexacerbationsloss
lung
functiontreatmentrel
advers
effect
factor
help
determin
level
treatment
requir
maintain
control
prevent
exacerb
wellcontrol
asthma
achiev
maintain
least
month
reduct
pharmacolog
therapi
consid
allow
use
minim
therapi
wellcontrol
asthma
wellcontrol
asthma
achiev
maintain
secondari
caus
assess
includ
patient
complianc
techniqu
use
medic
presenc
coexist
condit
provocateur
asthma
action
plan
review
essenti
patient
asthma
even
patient
mild
intermitt
asthma
may
experi
sudden
sever
exacerb
asthma
essenti
exacerb
recogn
earli
treatment
implement
action
plan
includ
symptom
worsen
asthma
peak
flow
meter
read
guidelin
recommend
use
rescu
therapi
increas
use
control
medic
administr
system
corticosteroid
seek
medic
care
exampl
asthma
action
plan
shown
tabl
sever
asthma
repres
case
asthma
patient
account
disproportion
share
health
cost
morbid
associ
diseas
sever
sever
asthma
phenotyp
describ
basi
age
patient
age
diseas
onset
corticosteroid
resist
chronic
airflow
obstruct
evid
eosinophil
airway
inflamm
biopsi
group
patient
particularli
import
diagnosi
asthma
confirm
correct
use
complianc
medic
confirm
possibl
exacerb
factor
airsmog
optim
manag
mainstay
pharmacotherapi
highdos
inhal
corticosteroid
longact
possibl
adjunct
longact
control
medic
includ
leukotrien
antagonist
theophyllin
omalizumab
anticholinerg
agent
system
corticosteroid
use
exacerb
may
requir
mainten
therapi
goal
use
littl
system
corticosteroid
possibl
maintain
stabl
airway
function
patient
asthma
control
everyotherday
corticosteroid
regimen
patient
requir
system
corticosteroid
need
monitor
treatment
side
effect
particularli
increas
glucos
level
diabet
mellitu
posterior
subcapsular
cataract
osteopenia
osteoporosi
monitor
corticosteroid
dosag
base
inflammatori
marker
sputum
eosinophil
nitric
oxid
hold
promis
futur
way
prescrib
littl
system
corticosteroid
possibl
variou
immunomodul
steroidspar
agent
attempt
year
gener
experi
methotrex
troleandomycin
gold
intraven
gamma
globulin
disappoint
patient
sever
asthma
requir
specialist
manag
condit
occup
asthma
diseas
character
variabl
outflow
obstruct
hyperrespons
due
caus
condit
attribut
particular
occup
environ
due
stimuli
encount
outsid
workplac
estim
case
asthma
industri
nation
occup
relat
occup
asthma
separ
two
main
subtyp
immunolog
nonimmunolog
immunolog
subtyp
subdivid
immunolog
mediat
asthma
hypersensit
pneumon
nonimmunolog
subtyp
due
irrit
type
reaction
usual
larg
exposur
offend
substanc
term
reactiv
airway
dysfunct
syndrom
rad
rad
character
high
level
exposur
offend
agent
acut
onset
asthma
symptom
persist
asthma
symptom
month
develop
airway
hyperreact
subsequ
irrit
exposur
exercis
cold
air
fume
etc
subtyp
overlap
mani
reactiv
chemic
caus
diseas
induc
immunolog
asthma
rad
substanc
exampl
western
red
cedar
pulmonari
respons
well
delin
either
immunolog
mediat
irrit
respons
agent
caus
occup
asthma
highmolecularweight
protein
plant
anim
bacteria
origin
lowmolecularweight
chemic
act
irrit
aggrav
underli
asthma
produc
rad
lowmolecularweight
chemic
also
form
immunolog
mediat
reaction
hapten
protein
respiratori
tract
enabl
bind
ige
common
caus
occup
asthma
list
tabl
asthma
subject
question
occup
also
work
environ
work
environ
histori
includ
detail
build
work
agent
chemic
work
directli
process
ongo
work
area
typic
symptom
occup
asthma
occur
work
improv
person
away
work
environ
progress
diseas
howev
relat
work
environ
symptom
becom
less
clearcut
particularli
true
worker
underli
asthma
whose
symptom
made
wors
nonspecif
irrit
work
poorli
control
asthma
also
worker
may
expos
offend
agent
everi
day
intermitt
exposur
hard
identifi
latenc
period
onset
exposur
onset
symptom
highli
variabl
gener
latenc
period
shorter
exposur
lowmolecularweight
agent
highmolecularweight
agent
initi
evalu
patient
first
confirm
whether
patient
inde
asthma
pulmonari
function
test
indic
obtain
baselin
pulmonari
function
determin
presenc
asthma
asthma
confirm
increas
administr
bronchodil
decreas
bronchoprovoc
exampl
methacholin
establish
asthma
occup
difficult
underli
principl
identifi
offend
substanc
show
sensit
skin
vitro
test
detect
object
chang
pulmonari
function
work
exposur
skin
vitro
test
substanc
present
work
environ
posit
suggest
causal
relat
mani
instanc
howev
reagent
skin
vitro
test
avail
also
rad
skin
vitro
test
neg
often
necessari
reproduc
symptom
challeng
challeng
may
conduct
natur
exposur
patient
work
environ
control
bronchoprovoc
suspect
substanc
laboratori
challeng
consist
normal
work
environ
exposur
serial
measur
pefr
help
one
method
monitor
patient
record
pefr
four
time
daili
week
work
similar
period
away
work
approach
sever
potenti
problem
includ
reproduc
read
complianc
honesti
patient
interpret
result
similarli
spirometri
perform
measur
workplac
compar
measur
made
nonwork
day
may
need
done
repeatedli
measur
singl
patient
work
instead
home
suffici
sensit
detect
relat
work
asthma
anoth
method
determin
effect
work
environ
induc
sputum
measur
eosinophil
increas
sputum
eosinophil
obtain
week
work
exposur
compar
sampl
obtain
week
work
exposur
increas
sensit
specif
occup
asthma
diagnosi
compar
pefr
monitor
alon
mani
worker
occup
asthma
recov
complet
even
leav
work
environ
earli
diagnosi
remov
work
environ
critic
goal
complet
recoveri
sometim
chang
made
work
environ
elimin
significantli
decreas
exposur
howev
level
exposur
legal
limit
base
toxic
may
still
precipit
igemedi
reaction
consult
industri
hygienist
may
help
measur
exposur
although
preemploy
screen
test
effect
predict
develop
occup
asthma
effort
made
educ
worker
manag
highrisk
industri
affect
worker
recogn
earli
preval
asthma
pregnanc
approxim
manag
asthma
pregnanc
uniqu
effect
pregnanc
asthma
effect
asthma
treatment
asthma
develop
fetu
mother
primari
goal
optim
fetal
matern
health
pregnanc
onethird
patient
asthma
experi
improv
symptom
onethird
experi
worsen
symptom
onethird
remain
first
trimest
gener
well
toler
asthma
patient
increas
symptom
exacerb
report
occur
commonli
week
gestat
fewer
symptom
exacerb
week
asthma
gener
remain
control
labor
deliveri
overal
first
trimest
last
month
pregnanc
appear
rel
free
asthma
exacerb
second
earli
third
trimest
potenti
increas
symptom
cours
asthma
often
consist
woman
success
pregnanc
mechan
respons
chang
cours
asthma
pregnanc
known
howev
chang
appear
due
random
fluctuat
diseas
possibl
includ
physiolog
chang
pregnanc
stress
underus
medic
infect
immunolog
respons
fetu
atop
chang
gener
principl
asthma
manag
pregnanc
differ
substanti
nonpregn
asthma
patient
primari
concern
control
asthma
avoid
asthma
medic
patient
need
educ
potenti
advers
effect
uncontrol
asthma
wellb
fetu
need
understand
treat
asthma
medic
safer
increas
asthma
symptom
may
lead
matern
fetal
hypoxia
goal
limit
activ
exacerb
normal
pulmonari
function
minim
chronic
symptom
minim
advers
effect
medic
object
assess
monitor
perform
pregnant
asthma
patient
patient
predict
increas
risk
asthma
morbid
pregnanc
complic
asthma
associ
decreas
fetal
growth
preterm
birth
accur
date
help
open
line
commun
patient
obstetrician
obstetrician
involv
manag
patient
asthma
obtain
inform
asthma
statu
prenat
visit
avoid
asthma
trigger
fume
tobacco
smoke
pollut
allergen
review
allergen
immunotherapi
continu
pregnanc
patient
toler
immunotherapi
well
without
system
reaction
mainten
dose
requir
escal
dose
immunotherapi
start
pregnanc
risk
system
reaction
buildup
phase
latenc
immunotherapi
effect
pharmacolog
manag
pregnant
women
asthma
updat
recent
document
naepp
work
group
report
manag
asthma
pregnanc
recommend
pharmacolog
treatment
updat
updat
superced
initi
report
updat
primari
recommend
includ
use
inhal
corticosteroid
prefer
control
therapi
mild
moder
persist
asthma
addit
moder
persist
asthma
combin
lowdos
inhal
corticosteroid
plu
longact
mediumdos
inhal
corticosteroid
consid
equal
treatment
option
fda
establish
five
categori
describ
drug
potenti
caus
advers
effect
pregnanc
tabl
categori
base
human
data
anim
studi
consider
whether
benefit
drug
use
pregnanc
outweigh
risk
asthma
allergi
medic
meet
requir
categori
appear
clearcut
recommend
choic
specif
medic
medic
categori
work
group
asthma
pregnanc
recogn
treatment
option
pregnanc
inhal
corticosteroid
use
time
name
beclomethason
dipropion
triamcinolon
flunisolid
experi
beclomethason
consid
inhal
corticosteroid
choic
sinc
report
support
overal
safeti
inhal
corticosteroid
pregnanc
current
avail
safeti
data
budesonid
consid
prefer
inhal
corticosteroid
pregnanc
data
suggest
corticosteroid
less
safe
pregnanc
therefor
pregnant
woman
asthma
use
altern
inhal
corticosteroid
well
reason
continu
medic
data
use
system
corticosteroid
pregnanc
rais
concern
although
definit
increas
risk
total
congenit
malform
statist
signific
increas
risk
oral
cleft
infant
mother
treat
oral
corticosteroid
first
trimest
shown
advers
outcom
associ
system
corticosteroid
use
includ
preeclampsia
low
birth
weight
preterm
deliveri
howev
difficult
determin
outcom
due
corticosteroid
underli
asthma
current
recommend
support
use
oral
corticosteroid
indic
longterm
manag
sever
asthma
sever
exacerb
pregnanc
initi
guidelin
make
recommend
specif
short
longact
basi
current
data
albuterol
recommend
inhal
shortact
choic
data
publish
safeti
salmeterol
formoterol
salmeterol
avail
longer
time
consid
longact
choic
medic
recommend
pregnanc
altern
choic
mild
persist
asthma
includ
cromolyn
theophyllin
zafirlukast
montelukast
theophyllin
zafirlukast
montelukast
also
use
addon
therapi
inhal
corticosteroid
serum
theophyllin
level
need
monitor
close
mainten
serum
level
target
practition
awar
potenti
side
effect
commonli
use
labor
medic
may
asthma
prostaglandin
ergonovin
methylergonovin
use
postpartum
hemorrhag
induc
bronchospasm
transcerv
intraamniot
prostaglandin
use
cervic
ripen
also
induc
bronchospasm
intravagin
intracerv
prostaglandin
gel
prostaglandin
suppositori
magnesium
sulfat
calcium
channel
blocker
safe
administ
asthma
patient
patient
receiv
regular
system
corticosteroid
therapi
receiv
frequent
burst
pregnanc
supplement
corticosteroid
recommend
stress
labor
deliveri
typic
stress
dose
mg
hydrocortison
intraven
admiss
repeat
everi
h
h
exerciseinduc
asthma
term
often
use
describ
bronchoconstrict
follow
exercis
asthma
patient
produc
symptom
cough
wheez
dyspnea
chest
tight
combin
also
term
accur
exerciseinduc
bronchoconstrict
exercis
induc
asthma
rather
exacerb
underli
asthma
exerciseinduc
asthma
occur
patient
asthma
occur
equal
frequenc
children
adult
preval
exerciseinduc
asthma
gener
popul
approxim
approxim
patient
condit
histori
asthma
allerg
diseas
magnitud
exerciseinduc
asthma
correl
underli
degre
airway
hyperrespons
therefor
mani
patient
mild
episod
asthma
even
strenuou
exercis
caus
clinic
signific
bronchoconstrict
underli
pathophysiolog
mechan
exerciseinduc
asthma
entir
clear
normal
breath
condit
major
warm
humidif
inspir
air
done
nasal
mucosa
vigor
exercis
larg
airway
recruit
provid
extra
heat
humid
condit
inspir
air
person
exercis
minut
ventil
increas
thu
respiratori
water
heat
loss
increas
disagr
rel
contribut
airway
water
loss
versu
airway
cool
versu
airway
rewarm
exercis
difficult
separ
role
potenti
trigger
exerciseinduc
asthma
shown
experiment
inhal
hot
dri
air
produc
condit
attenu
inspir
ga
humifi
closer
bodi
temperatur
impli
water
loss
princip
trigger
interest
observ
approxim
patient
exerciseinduc
asthma
refractori
exerciseinduc
symptom
exercis
within
min
first
exercis
session
howev
second
exercis
challeng
h
first
refractori
period
lost
symptom
similar
first
exercis
session
refractori
period
occur
patient
pretreat
indomethacin
suggest
prostaglandin
help
provid
protect
refractori
period
observ
exerciseinduc
asthma
includ
increas
inflammatori
mediat
includ
histamin
leukotrien
activ
peripher
lymphocyt
eosinophil
influx
activ
contrast
exhal
nitric
oxid
level
appear
correl
well
develop
sever
exerciseinduc
asthma
primari
symptom
associ
exerciseinduc
asthma
includ
combin
cough
dyspnea
chest
tight
chest
discomfort
wheez
symptom
may
occur
exercis
usual
min
exercis
min
complet
exercis
symptom
typic
clear
within
min
exercis
complet
note
refractori
period
h
initi
exercis
exercis
resum
within
time
littl
bronchoconstrict
occur
symptom
usual
pronounc
aerob
exercis
bicycl
run
crosscountri
ski
involv
signific
increas
ventilatori
rate
activ
less
aerob
weight
lift
dive
yoga
less
like
trigger
exerciseinduc
asthma
patient
usual
note
symptom
increas
exercis
cold
dri
air
compar
warm
moist
air
convent
exerciseinduc
asthma
test
perform
laboratori
min
treadmil
exercis
suffici
increas
heart
rate
predict
maximum
spirometri
perform
exercis
least
patient
predict
valu
spirometri
repeat
immedi
upon
complet
exercis
repeat
min
exercis
stop
lowest
postexercis
valu
obtain
compar
preexercis
level
decreas
consid
posit
test
spirometri
avail
peak
expiratori
flow
rate
also
use
also
obtain
exercis
repeat
upon
complet
exercis
min
exercis
initi
peak
flow
read
person
best
decreas
consid
posit
test
diagnosi
unclear
despit
attempt
measur
pulmonari
function
evalu
requir
primari
differenti
diagnosi
exerciseinduc
respiratori
symptom
includ
normal
physiolog
exercis
limit
upper
airway
obstruct
vocal
cord
dysfunct
parenchym
pulmonari
diseas
cardiac
disord
evalu
may
requir
formal
exercis
test
referr
center
use
pulmonari
function
test
lung
volum
diffus
capac
oxygen
satur
sever
nonpharmacolog
therapeut
modal
avail
aid
treatment
exerciseinduc
asthma
patient
advis
warmup
period
strenuou
exercis
consist
min
stretch
mild
exercis
warmup
may
help
decreas
sever
exerciseinduc
asthma
patient
encourag
increas
cardiovascular
fit
improv
overal
fit
lower
minut
ventil
requir
given
level
exercis
therebi
decreas
one
primari
stimuli
bronchoconstrict
breath
warm
humidifi
air
help
nasal
breath
recommend
similarli
patient
instruct
breath
loos
fit
scarf
mask
exercis
cold
dri
condit
humidifi
air
pharmacotherapi
exerciseinduc
asthma
vari
clinic
set
gener
exerciseinduc
asthma
occur
poorli
control
asthma
import
strategi
improv
overal
control
underli
asthma
underli
asthma
well
control
treatment
strategi
exercisedinduc
symptom
provocateur
airway
hyperreact
inhal
shortact
primari
prophylact
treatment
exerciseinduc
asthma
significantli
reduc
elimin
condit
patient
typic
dose
two
puff
albuterol
taken
min
exercis
protect
exerciseinduc
asthma
approxim
h
although
durat
bronchodil
nearli
h
anoth
approach
use
chromon
inhal
cromolyn
nedocromil
may
consid
patient
shortact
fulli
effect
dosag
rang
puff
min
exercis
addit
may
synergist
effect
use
combin
longact
also
shown
effect
prophylaxi
exerciseinduc
asthma
advantag
medic
may
taken
hour
exercis
concern
develop
toler
drug
time
leukotrien
receptor
antagonist
also
shown
benefit
exerciseinduc
asthma
long
halflif
agent
allow
protect
exerciseinduc
asthma
h
ingest
inhal
corticosteroid
prevent
exerciseinduc
asthma
short
term
longterm
use
howev
improv
airway
hyperrespons
decreas
bronchoconstrict
associ
exert
patient
experi
acut
breakthrough
symptom
despit
prophylact
treatment
absenc
prophylact
treatment
primari
treatment
shortact
prophylact
measur
chromon
leukotrien
antagonist
effect
acut
treatment
exerciseinduc
asthma
allerg
bronchopulmonari
aspergillosi
abpa
complex
hypersensit
reaction
antigen
aspergillu
fumigatu
ubiquit
airborn
fungu
reaction
occur
primarili
patient
asthma
cystic
fibrosi
aspergillu
spore
within
bronchial
tree
activ
immun
system
caus
tissu
inflamm
result
proxim
bronchiectasi
bronchiol
obliteran
abpa
occur
patient
persist
asthma
cystic
fibrosi
abpa
occur
asthma
sever
common
patient
moder
sever
persist
asthma
pathogenesi
abpa
incomplet
understood
tcell
like
import
role
gener
cytokin
contribut
eosinophilia
elev
ige
seen
abpa
addit
eosinophil
inflamm
enzym
toxin
releas
fungi
neutrophilicmedi
inflamm
like
contribut
airway
damag
central
bronchiectasi
besid
histolog
featur
asthma
abpa
character
mucoid
impact
bronchi
bronchocentr
granulomatosi
fungi
invad
mucosa
instead
serv
instig
immun
respons
clinic
present
abpa
character
persist
asthma
complic
recurr
episod
bronchial
obstruct
expector
brownish
mucou
plug
difficulttocontrol
asthma
singl
test
confirm
diagnosi
abpa
mark
inflammatori
respons
sever
laboratori
abnorm
typic
note
diagnost
criteria
abpa
includ
follow
histori
asthmaposit
skin
prick
test
vitro
test
fumigatu
elev
serum
level
igg
ige
fumigatu
elev
total
serum
ige
ng
eosinophilia
pulmonari
infiltr
chest
xray
chest
ctcentral
bronchiectasi
make
diagnosi
abpa
histori
asthma
cystic
fibrosi
posit
skin
prick
test
vitro
test
fumigatu
document
criteria
howev
asthma
patient
ige
sensit
fumigatu
without
abpa
approxim
asthma
patient
posit
immedi
skin
prick
test
fumigatu
diagnosi
abpa
seroposit
made
first
four
criteria
met
diagnosi
abpacb
central
bronchiectasi
made
criteria
met
stage
system
also
devis
abpastag
acut
patient
first
appear
abpasstag
remiss
ige
level
decreas
peak
igestag
exacerb
new
radiograph
infiltr
ige
doublesstag
corticosteroid
depend
prednison
taper
without
worsen
asthma
symptom
increas
ige
level
develop
radiograph
infiltratesstag
fibrosi
lung
fibrot
pulmonari
function
test
show
restrict
defect
irrevers
obstruct
treatment
abpa
design
control
episod
acut
inflamm
prevent
develop
progress
lung
injuri
fibrosi
acut
flare
abpa
stage
treat
mg
prednison
day
follow
reduct
everyotherday
dose
taper
month
total
serum
ige
excel
marker
diseas
monitor
week
monthli
bimonthli
year
clinic
improv
gener
accompani
decreas
serum
ige
serum
ige
decreas
one
consid
medicin
noncompli
continu
abpa
exacerb
anoth
diagnosi
patient
treat
earli
aggress
diseas
progress
stage
corticosteroid
appear
benefit
stage
diseas
itraconazol
also
studi
abpa
administ
place
corticosteroid
abpa
itraconazol
may
provid
addit
benefit
corticosteroid
treatment
consid
patient
slow
poor
respons
corticosteroid
stage
diseas
daili
dose
exceed
mg
typic
durat
therapi
month
itraconazol
therapi
liver
function
test
monitor
monthli
syndrom
system
smallvessel
vascul
occur
patient
sever
asthma
sinus
four
differ
definit
diagnosi
syndrom
develop
patholog
criteria
churg
strauss
clinic
criteria
lanham
colleagu
clinic
criteria
american
colleg
rheumatolog
criteria
chapel
hill
concensu
confer
tabl
syndrom
system
diseas
develop
patient
histori
upper
airway
diseas
sinus
involv
organ
vari
typic
includ
heart
gastrointestin
tract
cerebr
vessel
joint
muscl
skin
nerv
singl
confirmatori
laboratori
test
syndrom
diagnosi
depend
clinic
present
diseas
histolog
hallmark
tissu
eosinophilia
essenti
blood
eosinophilia
untreat
patient
almost
alway
present
although
perinuclear
antineutrophil
cytoplasm
antibodi
panca
usual
detect
absenc
rule
syndrom
syndrom
consid
patient
moder
sever
asthma
follow
featur
newonset
footdrop
mononeur
multiplex
palpabl
purpura
bruis
chronic
urticarialtyp
lesion
smallvessel
vascul
dermal
blood
vessel
migratori
pulmonari
infiltr
eosinophil
infiltr
lung
cardiac
enlarg
without
failur
associ
symptom
includ
decreas
appetit
paresthesia
headach
arthralgia
abdomin
pain
proteinuria
hematuria
worsen
sinus
differenti
diagnosi
includ
hypereosinophil
syndrom
vasculitid
abpa
hyperplast
rhinosinus
nasal
polyposi
eosinophil
pneumonia
parasit
diseas
drug
allergi
laboratori
evalu
includ
complet
blood
count
differenti
cell
count
anca
studi
erythrocyt
sediment
rate
urinalysi
chest
radiographi
aspergillu
skin
test
total
ige
stool
examin
ova
parasit
biopsi
diagnost
biopsi
perform
access
affect
tissu
biopsi
site
affect
clinic
limit
valu
therefor
discourag
help
biopsi
site
includ
sural
nerv
affect
muscl
patient
footdrop
skin
biopsi
purpura
lung
biopsi
migratori
pulmonari
infiltr
clinic
cours
syndrom
vari
proven
marker
diseas
activ
nevertheless
monitor
blood
eosinophil
count
acut
phase
reactant
gener
recommend
monitor
diseas
activ
elev
may
presag
clinic
exacerb
help
physician
guid
medic
manag
patient
evid
activ
vascul
corticosteroid
immunosuppress
agent
consid
firstlin
therapi
treatment
syndrom
requir
high
dose
corticosteroid
adjust
dose
base
diseas
respons
corticosteroid
therapi
induc
remiss
primari
immunosuppress
agent
use
cyclophosphamid
man
present
continu
cough
dyspnea
wheez
previou
histori
respiratori
problem
year
ago
concomit
sinus
cough
dyspnea
wheez
develop
time
evalu
show
follow
normal
chest
radiograph
pulmonari
function
test
markedli
decreas
ratio
l
predict
normal
dlco
coron
sinu
ct
chronic
pansinus
nasal
polyp
neg
anca
studi
normal
ige
neg
allergen
skin
prick
test
common
aeroallergen
includ
aspergillu
subsequ
function
endoscop
sinu
surgeri
sinu
symptom
improv
significantli
howev
cours
year
continu
cough
dyspnea
wheez
essenti
daili
state
nighttim
symptom
state
health
problem
specif
skin
rash
weak
kidney
problem
current
report
take
combin
fluticason
salmeterol
advair
one
puff
twice
daili
prednison
mg
per
day
montelukast
singulair
mg
per
day
pantoprazol
protonix
mg
per
day
albuterol
inhal
approxim
daili
physic
examin
show
normal
vital
sign
normal
skin
ear
nose
throat
examin
normal
cardiac
examin
unremark
lung
examin
notabl
scatter
mild
expiratori
wheez
increas
breath
sound
sternal
notch
inspiratori
breath
sound
current
spirometri
show
decreas
ratio
l
predict
inspiratori
loop
normal
peripher
blood
eosinophil
undetect
chest
radiograph
find
unremark
comment
situat
repres
difficult
process
patient
current
symptomat
despit
prednison
therapi
intens
asthma
manag
program
alway
sever
asthma
steroiddepend
asthma
one
must
ensur
asthma
correct
diagnosi
case
patient
clinic
symptom
pulmonari
function
test
compat
asthma
consider
assess
includ
special
subset
asthma
abpa
unlik
given
neg
aspergillu
skin
test
normal
ige
syndrom
unlik
given
lack
peripher
eosinophilia
neg
anca
studi
lack
skin
neurolog
symptom
condit
includ
cardiac
condit
upper
airway
disord
pulmonari
condit
also
assess
basi
studi
thorough
physic
examin
condit
appear
involv
point
next
step
consid
factor
contribut
asthma
main
issu
address
complianc
techniqu
evalu
exacerb
use
mnemon
airsmog
includ
allergen
irrit
rhinosinus
smoke
medic
occup
histori
gastroesophag
reflux
issu
review
patient
complianc
appear
issu
wife
quit
clear
confirm
medic
schedul
techniqu
issu
note
use
fluticasonesalmeterol
inhal
incorrectli
given
instruct
observ
use
medic
master
possibl
exacerb
asthma
review
allergen
thought
like
factor
base
neg
skin
prick
test
common
aeroallergen
exposur
irrit
home
rhinosinus
stabl
sinc
surgeri
receiv
mainten
treatment
intranas
corticosteroid
salin
irrig
nonsmok
take
medic
either
pill
eye
drop
form
retir
continu
haul
fertil
truck
occup
would
occasion
note
increas
symptom
load
unload
truck
often
forgot
wear
mask
load
unload
although
histori
gastroesophag
reflux
well
control
pantoprazol
comment
review
uncov
area
improv
main
area
improv
inhal
techniqu
use
mask
load
unload
fertil
also
maxim
inhal
regimen
fluticasonesalmeterol
increas
high
dose
one
puff
twice
daili
plan
slow
prednison
taper
followup
month
later
patient
note
signific
improv
although
still
requir
prednison
mg
per
day
maintain
good
symptom
control
develop
symptom
continu
inhal
regimen
rhinosinus
treatment
evalu
show
peripher
eosinophil
normal
sputum
eosinophil
normal
exhal
nitric
oxid
part
per
billion
normal
increas
predict
comment
patient
would
consid
sever
asthma
basi
medic
requir
keep
symptom
control
appear
lateonset
eosinophil
inflamm
phenotyp
phenotyp
uncommon
concomit
sinu
diseas
phenotyp
typic
difficult
treat
patient
requir
close
followup
prevent
measur
place
close
monitor
corticosteroid
advers
effect
particularli
posterior
subcapsular
cataract
osteoporosi
complianc
techniqu
exacerb
factor
airsmog
need
assess
routin
develop
syndrom
kept
mind
goal
decreas
corticosteroid
dose
whenev
possibl
base
symptom
pulmonari
function
inflammatori
paramet
femal
nurs
histori
anxieti
present
evalu
asthma
symptom
develop
past
month
despit
use
daili
highdos
inhal
corticosteroid
longact
frequent
use
albuterol
continu
symptom
dyspnea
cough
associ
time
feel
wheez
state
symptom
rhiniti
gastroesophag
reflux
respiratori
symptom
occur
either
randomli
sometim
exposur
strong
odor
strong
associ
exercis
feel
wors
increas
stress
treat
oral
corticosteroid
three
time
past
month
current
asymptomat
physic
examin
find
close
attent
paid
ear
nose
throat
heart
lung
examin
complet
normal
previou
evalu
includ
chest
radiographi
spirometri
electrocardiographi
echocardiographi
result
normal
comment
alreadi
mani
test
perform
nonrev
extrem
import
obtain
good
descript
dyspnea
wheez
patient
describ
dyspnea
typic
occur
suddenli
within
minut
quickli
go
feel
fine
feel
short
breath
get
deep
breath
sometim
symptom
last
min
time
day
episod
asymptomat
albuterol
seem
help
use
sure
prednison
made
differ
symptom
describ
wheez
loud
breath
typic
pronounc
inspir
comment
detail
symptom
help
sudden
onset
symptom
seen
asthma
asthma
gener
slower
onset
lack
benefit
albuterol
prednison
highli
suggest
process
asthma
noisi
breath
inspir
may
consist
stridor
wheez
stridor
sign
upper
airway
obstruct
fix
upper
airway
obstruct
symptom
typic
precipit
initi
exert
may
progress
point
occur
rest
current
asymptomat
would
help
evalu
time
symptomat
patient
return
symptomat
appear
dyspneic
respiratori
rate
breath
per
minut
audibl
stridor
puls
oximetri
normal
oxygen
satur
lung
examin
show
increas
breath
sound
sternal
notch
inspir
chest
clear
comment
physic
examin
find
typic
asthma
upper
airway
process
suggest
stridor
increas
breath
sound
sternal
notch
evalu
upper
airway
need
patient
symptomat
rhinolaryngoscopi
perform
show
paradox
vocal
cord
adduct
inspir
comment
find
diagnost
vocal
cord
dysfunct
unfortun
often
difficult
perform
rhinolaryngoscopi
patient
symptomat
inspiratori
loop
perform
patient
symptomat
help
would
show
flatten
inspiratori
loop
normal
expiratori
loop
manag
vocal
cord
dysfunct
includ
speech
therapi
treatment
possibl
exacerb
factor
anxieti
depress
gastroesophag
reflux
rhiniti
woman
present
first
trimest
pregnanc
evalu
asthma
describ
histori
mild
asthma
date
back
childhood
never
hospit
asthma
requir
emerg
depart
visit
month
ago
believ
asthma
worsen
previou
pregnanc
year
ago
current
describ
daili
symptom
wheez
short
breath
nighttim
symptom
twice
weekli
use
albuterol
inhal
three
time
daili
prescrib
inhal
corticosteroid
month
ago
discontinu
month
ago
discov
pregnant
intermitt
rhiniti
symptom
say
gastroesophag
reflux
think
asthma
wors
clean
hous
cat
home
last
year
smoke
cigarett
physic
examin
show
scatter
endexpiratori
wheez
spirometri
show
decreas
ratio
predict
improv
predict
two
puff
inhal
albuterol
comment
patient
mildtomoder
persist
asthma
optim
control
effort
improv
asthma
educ
undertaken
explain
manag
asthma
pregnanc
emphas
main
risk
babi
common
medic
use
treat
asthma
rather
poorli
control
asthma
allergi
test
particularli
dust
mite
cat
would
help
assess
possibl
exacerb
asthma
risk
worsen
asthma
pregnanc
occur
last
pregnanc
allergi
skin
test
strongli
posit
dust
mite
neg
cat
comment
comprehens
asthma
manag
plan
outlin
includ
follow
educ
asthma
pregnanc
environment
measur
decreas
dust
mite
exposur
primarili
encas
mattress
pillow
allergenimperm
cover
wash
bed
hot
water
weekli
institut
lowdos
inhal
corticosteroid
instruct
inhal
techniqu
peak
flow
rate
instruct
develop
peak
flowbas
asthma
action
plan
followup
week
schedul
visit
thereaft
easi
avail
problem
schedul
visit
woman
present
evalu
histori
chest
tight
nonproduct
cough
dyspnea
patient
report
longstand
histori
mild
allerg
rhiniti
symptom
primarili
spring
fall
howev
symptom
rather
constant
past
year
recal
respiratori
problem
asthma
diagnos
child
patient
never
smoke
chang
home
environ
past
decad
say
take
prescript
overthecount
medic
symptom
gastroesophag
reflux
overal
good
gener
health
vital
sign
normal
nasal
examin
notabl
boggi
edema
inferior
turbin
small
amount
clearish
discharg
heart
examin
normal
lung
examin
show
scatter
expiratori
wheez
spirometri
show
slightli
decreas
ratio
predict
improv
predict
two
puff
albuterol
comment
patient
histori
physic
examin
find
spirometri
consist
rhiniti
asthma
although
histori
season
allergi
clear
persist
rhiniti
asthma
develop
inform
requir
home
work
environ
search
clue
may
progress
patient
relat
live
home
past
year
major
remodel
done
damp
water
damag
pet
howev
report
chang
job
approxim
year
ago
previous
work
cashier
work
bakeri
local
supermarket
primari
job
cake
decor
bake
question
thought
symptom
wors
day
bake
cake
better
day
work
histori
food
allergi
comment
possibl
increas
symptom
includ
new
sensit
dust
mite
occup
exposur
patient
report
increas
symptom
work
rais
question
occup
asthma
bakeri
wheat
flour
common
allergen
follow
soy
flour
role
occup
exposur
measur
patient
stay
work
week
remeasur
perform
serial
peak
flow
work
exposur
patient
stay
home
work
week
treat
respiratori
symptom
inhal
albuterol
symptom
well
control
albuterol
albuterol
discontinu
h
followup
visit
end
week
followup
visit
lung
clear
auscult
spirometri
show
baselin
predict
normal
ratio
allergen
skin
prick
test
markedli
posit
wheat
flour
neg
soy
flour
dust
mite
comment
find
consist
allergi
inhal
wheat
flour
baker
asthma
result
allerg
rhiniti
asthma
ideal
move
area
limit
exposur
wheat
flour
continu
exposur
wheat
flour
would
result
persist
rhiniti
asthma
symptom
import
treat
rhiniti
part
asthma
manag
mask
aggress
pharmacolog
measur
includ
intranas
corticosteroid
inhal
corticosteroid
inhal
need
use
patient
remain
job
howev
would
ideal
femal
day
care
worker
histori
mild
persist
asthma
develop
persist
cough
maxillari
discomfort
purul
nasal
secret
day
contract
upper
respiratori
tract
infect
asthma
worsen
report
partial
relief
use
inhal
albuterol
physic
examin
notabl
lowgrad
temperatur
right
maxillari
tender
purul
nasal
secret
scatter
endexpiratori
wheez
peak
expiratori
flow
l
predict
initi
treatment
includ
amoxicillinclavulan
augmentin
mg
twice
daili
increas
daili
inhal
steroid
budesonid
one
puff
twice
daili
two
puff
twice
daili
albuterol
mdi
two
puff
need
everi
h
comment
patient
upper
respiratori
tract
infect
sinus
worsen
asthma
upper
respiratori
tract
infect
common
trigger
acut
worsen
asthma
increas
inhal
corticosteroid
may
help
improv
asthma
exacerb
like
effect
done
earlier
cours
sinus
treat
appropri
amoxicillinclavulan
patient
return
day
later
increas
short
breath
chest
tight
cough
use
albuterol
inhal
time
daili
mild
improv
symptom
physic
examin
afebril
frequent
cough
respiratori
rate
breath
per
minut
lung
examin
show
scatter
expiratori
wheez
throughout
lung
field
crackl
peak
flow
l
predict
given
albuterol
mg
ml
salin
nebul
prednison
mg
mouth
follow
nebul
lung
examin
show
decreas
expiratori
wheez
good
air
movement
peak
flow
rate
improv
l
subject
patient
felt
better
prescrib
prednison
mg
per
day
day
albuterol
inhal
two
puff
everi
h
continu
budesonid
two
puff
twice
daili
plan
made
followup
day
sooner
symptom
worsen
comment
patient
even
mild
asthma
sever
exacerb
conjunct
respiratori
infect
requir
aggress
treatment
earlier
use
highdos
inhal
corticosteroid
oral
prednison
may
prevent
sever
exacerb
followup
day
later
lung
examin
show
rare
expiratori
wheez
peak
flow
increas
l
ask
continu
budesonid
two
puff
twice
daili
week
probabl
resumpt
one
puff
twice
daili
time
comment
patient
signific
improv
use
oral
prednison
even
though
condit
clinic
improv
asthma
particularli
inflammatori
viewpoint
return
baselin
help
prevent
relaps
hasten
recoveri
preexacerb
level
continu
higher
dose
inhal
corticosteroid
week
time
followup
examin
review
peak
flow
measur
aid
reestablish
manag
program
